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PREDICTIVE VALUE OF STEROIDAL HORMONES TO TYPE 2 
DIABETES AND METABOLIC SYNDROME 
DUSTIN R. BUNCH 
ABSTRACT 
 Metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM) are highly 
prevalent in the US population and major health burdens. Consensus criterion for 
diagnosis of MetS was proposed by the International Diabetes Federation. The American 
Diabetes Association (ADA) has issued diagnosis criteria for T2DM that are 
internationally implemented. Steroid hormones especially aldosterone, testosterone, and 
cortisol have been found to be correlated with these disease states. A logistic regression 
model is used to determine the predictive value of the measured steroid hormones.  
In Chapter 1, we develop the background on steroids specifically cortisol which is 
directly related to the subsequent chapters. Steroid pathways and the hypothalamus 
pituitary adrenal axis are discussed. In the remaining chapters, solutions are proposed for 
measurement of various steroid panels, which involve liquid chromatography-tandem 
mass spectrometry (LC-MS/MS). Chapter 2 discusses LC-MS/MS technique, 
development, and validation of clinical assays. Chapter 3 introduces a LC-MS/MS steroid 
panel for the measurement of plasma testosterone, aldosterone, cortisol, and cortisone and 
the predictive value of these compounds for MetS and T2DM. Cortisone had a strong 
predictive value for T2DM based on a logistic regression model of the data. Chapter 4 
introduces a new LC-MS/MS method for the measurement of salivary cortisol, which is 
useful for identifying Cushing’s disease. This method is simple and fast and has been 
 vii 
used for clinical studies. A reference interval collection was performed and the salivary 
cortisol reference interval was verified. Chapter 5 introduces a third LC-MS/MS method 
that measures a panel of steroids for the detection of congenital adrenal hyperplasia that 
is able to identify all the possible enzymatic blockages for this disease. 
 viii 
TABLE OF CONTENTS 
ABSTRACT… ................................................................................................................... vi 
LIST OF TABLES ............................................................................................................ xii 
LIST OF FIGURES .......................................................................................................... xv 
CHAPTER  
I. STEROIDS AND DISEASE ................................................................................ 1 
1.1. STEROID OVERVIEW ................................................................................ 1 
1.1.1. Major Site of Steroid Production .................................................. 2 
1.1.2. Steroid Regulation ........................................................................ 7 
1.1.3. Steroids and Diseases ................................................................... 9 
1.2. IMMUNOASSAYS VS. LC-MS/MS ........................................................... 11 
1.3. REFERENCES .......................................................................................... 13 
II. LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY 
METHOD DEVELOPMENT AND VALIDATION ............................................. 16 
2.1. INTRODUCTION TO LIQUID CHROMATOGRAPHY-TANDEM MASS 
SPECTROMETRY ............................................................................................... 16 
2.1.1. Liquid Chromatography-Tandem Mass Spectrometry in the 
Clinical Laboratory ................................................................................ 16 
2.1.2. Liquid Chromatography-Triple Quadrupole Mass Spectrometry21 
2.1.3. LC-MS/MS Method Development ............................................. 24 
2.1.4. Sample Preparation Optimization ............................................... 45 
 ix 
2.2. LC-MS/MS METHOD VALIDATION ....................................................... 48 
2.2.1. Matrix Effects ............................................................................. 48 
2.2.2. Mixing Study .............................................................................. 50 
2.2.3. Method Interference (based on CLSI EP7-A2 guideline) .......... 50 
2.2.4. Analytical Measurement Range (AMR)/Linearity/Calibration .. 51 
2.2.5. Method Carryover ....................................................................... 51 
2.2.6. Assay Precision ........................................................................... 52 
2.2.7. Method Comparisons .................................................................. 52 
2.3. CONCLUSION .......................................................................................... 53 
2.4. REFERENCES .......................................................................................... 53 
III. PREDICTIVE VALUE OF STEROIDAL HORMONES TO TYPE 2 
DIABETES AND METABOLIC SYNDROME ................................................... 56 
3.1. BACKGROUND ........................................................................................ 56 
3.1.1. Metabolic syndrome ................................................................... 57 
3.1.2. Type 2 diabetes mellitus ............................................................. 58 
3.2. METHOD DEVELOPMENT AND VALIDATION ............................................ 63 
3.2.1. Chemicals, reagents and solutions .............................................. 63 
3.2.2. Sample Preparation ..................................................................... 64 
3.2.3. LC-MS/MS method .................................................................... 66 
3.2.4. Method validation procedure ...................................................... 70 
3.2.5. Sample Collection ....................................................................... 71 
3.3. RESULTS ................................................................................................ 72 
3.3.1. Method validation ....................................................................... 72 
 x 
3.3.2. Sample statistics .......................................................................... 78 
3.4. CONCLUSION .......................................................................................... 91 
3.5. REFERENCES .......................................................................................... 92 
IV. VERIFICATION OF MORNING AND LATE NIGHT SALIVARY 
CORTISOL REFERENCE INTERVALS FROM A REFERENCE POPULATION 
USING A QUANTITATIVE LC-MS/MS METHOD ........................................... 96 
4.1. BACKGROUND ........................................................................................ 96 
4.2. MATERIAL AND METHODS ...................................................................... 97 
4.2.1. Chemicals, reagents and solutions .............................................. 97 
4.2.2. Sample Preparation ..................................................................... 98 
4.2.3. LC-MS/MS method .................................................................... 98 
4.2.4. Method validation ..................................................................... 101 
4.2.5. Sample collection for reference range study ............................ 102 
4.3. RESULTS AND DISCUSSION ................................................................... 103 
4.3.1. Chromatography ....................................................................... 103 
4.3.2. Assay validation ........................................................................ 104 
4.4. CONCLUSION ........................................................................................ 109 
4.5. REFERENCES ........................................................................................ 109 
V. LC-MS/MS METHOD FOR CONGENITAL ADRENAL HYPERPLASIA 111 
5.1. BACKGROUND ...................................................................................... 111 
5.2. METHODS AND MATERIALS .................................................................. 115 
5.2.1. Chemicals, reagents and solutions ............................................ 115 
5.2.2. Calibrators and Quality Controls .............................................. 115 
 xi 
5.2.3. Sample Preparation ................................................................... 116 
5.2.4. LC-MS/MS method .................................................................. 119 
5.2.5. Method validation ..................................................................... 122 
5.3. RESULTS AND DISCUSSION ................................................................... 123 
5.4. CONCLUSION ........................................................................................ 127 
5.5. REFERENCES ........................................................................................ 127 
VI. OVERALL CONCLUSIONS AND FUTURE DIRECTIONS ..................... 131 
6.1. CHAPTER 2 ........................................................................................... 131 
6.2. CHAPTER 3 ........................................................................................... 132 
6.2.1. Prospective follow-up study ..................................................... 132 
6.2.2. NHANES proposal ................................................................... 132 
6.3. CHAPTER 4 ........................................................................................... 132 
6.4. CHAPTER 5 ........................................................................................... 132 
6.5. REFERENCES ........................................................................................ 133 
 
 xii 
LIST OF TABLES 
Table               Page 
1.1. Biological Effects of Cortisol. ................................................................................... 12 
2.1: Analysis of LC-MS Strength, Weakness, Opportunities, and Threats (SWOT) in 
Clinical Diagnostics.. ................................................................................................ 19 
2.2: Comparison of the General Features of Single and Triple Quad Instruments with 
Quadrupole-Time-Of-Flight (Q-TOF) and Linear Ion Trap Orbitrap (LTQ-orbitrap)..
 ................................................................................................................................... 20 
2.3: Pregnenolone Derivations Normalized to Reserpine Ionization ................................ 31 
2.4: Cortisol Single Keto-group Derivations Normalized to Reserpine Ionization .......... 32 
2.5: Cortisol Double Keto-group Derivations Normalized to Reserpine Ionization ........ 33 
2.6: Cortisone Single Keto-group Derivations Normalized to Reserpine Ionization ....... 34 
2.7: Cortisone Double Keto-group Derivations Normalized to Reserpine Ionization ...... 35 
2.8: Cortisone Triple Keto-group Derivations Normalized to Reserpine Ionization ........ 36 
2.9: Aldosterone Single Keto-group Derivations Normalized to Reserpine Ionization ... 37 
2.10: Aldosterone Double Keto-group Derivations Normalized to Reserpine Ionization 38 
2.11: Aldosterone Triple Keto-group Derivations Normalized to Reserpine Ionization .. 39 
2.12: Testosterone Derivations Normalized to Reserpine Ionization ............................... 40 
2.13: 17-Hydroxyprogesterone Single Keto-group Derivations Normalized to Reserpine 
Ionization .................................................................................................................. 41 
 xiii 
2.14: 17-Hydroxyprogesterone Double Keto-group Derivations Normalized to Reserpine 
Ionization .................................................................................................................. 42 
2.15: 11-deoxycortisol Single Keto-group Derivations Normalized to Reserpine 
Ionization .................................................................................................................. 43 
2.16: 11-deoxycortisol Double Keto-group Derivations Normalized to Reserpine 
Ionization .................................................................................................................. 44 
3.1 MetS Definition from the IDF .................................................................................... 61 
3.2: Criteria for the Diagnosis of Diabetes ....................................................................... 62 
3.3. Calibration Levels for MetS/T2DM Steroid Panel .................................................... 65 
3.4: MetS/T2DM Steroid Panel Chromatography Conditions .......................................... 68 
3.5:  MetS/T2DM Steroid Panel SRM Transitions and Collision Energy ........................ 69 
3.6: Aldosterone AMR Data ............................................................................................. 73 
3.7: Cortisone AMR Data ................................................................................................. 74 
3.8: Cortisol AMR Data .................................................................................................... 75 
3.9: Testosterone AMR Data ............................................................................................ 76 
3.10: MetS/T2DM Steroid Panel Precision ...................................................................... 77 
3.11: Patient Specimen Characteristics ............................................................................. 80 
3.12: Logit Regression Coefficients and p-values for MetS ............................................. 87 
3.13: Logit Regression Coefficients and p-values for T2DM .......................................... 89 
4.1: Salivary Cortisol Chromatography Conditions........................................................ 100 
 xiv 
4.2: Precision and Recovery Data from the AMR Study ................................................ 106 
5.1: Steroid Concentrations in Calibrators and Quality Controls ................................... 117 
5.2: Isotope-Replaced Working Internal Standard.......................................................... 118 
5.3: CAH Steroid Panel LC Conditions for Turbo and Analytical Columns.................. 120 
5.4: CAH Steroid Panel SRM Transitions ...................................................................... 121 
5.5: CAH Steroid Panel Validation Data Summary........................................................ 125 
5.6: CAH Steroid Panel Precision ................................................................................... 126 
 
 xv 
LIST OF FIGURES 
Figure              Page 
1.1: Human Steroidogenesis Pathway. Reproduced from [2]. ............................................ 4 
1.2: Adrenal Glands ............................................................................................................ 5 
1.3: Labeled Microscope Picture of Cross-section Adrenal Gland..................................... 6 
1.4: Detailed Control Mechanisms for RAAS. ................................................................. 10 
2.1: Dynamic Range of Low Molecular Weight Biomarkers in Adult Human Serum.. ... 18 
2.2: Illustration of the Steps Involved in LC-MS/MS Analysis.. ..................................... 23 
2.3: Possible Derivation Reagents. ................................................................................... 28 
2.4: Schiff Base Reaction with an Imine and Hydrazine .................................................. 29 
2.5: Schiff Base Reaction Mechanism .............................................................................. 30 
2.6: Graphical Depiction of Sample Preparation Methods... ............................................ 47 
2.7: Post-Column Infusion Set-Up Used to Evaluate The Effect of Absolute Ion 
Suppression.. ............................................................................................................. 49 
3.1: Steroid Panel Chromatogram. .................................................................................... 67 
3.2: Box-and-Whisker Plot of Male Testosterone Values. ............................................... 81 
3.3: Box-and-Whisker Plot of Female Testosterone Values. ............................................ 82 
3.4: Box-and-Whisker Plot of Combined Male and Female Cortisol Values................... 83 
3.5: Box-and-Whisker Plot of Combined Male and Female Cortisone Values. ............... 84 
 xvi 
3.6: ROC Curve for MetS and Various Individual Analytes. ........................................... 85 
3.7: ROC Curve for T2DM and Various Individual Analytes. ......................................... 86 
3.8: ROC Curve for MetS using the Logit Regression of Values in Table 3.12. ............. 88 
3.9: ROC Curve for T2DM using the Logit Regression of Values in Table 3.13. ........... 90 
4.1:  A Representative Chromatogram............................................................................ 105 
4.2: Reference Range Study. ........................................................................................... 108 
5.1: Steroidogenesis pathway.......................................................................................... 114 
5.2: Representative Chromatograms of Extracted Patient Serum...................................124 
 1 
CHAPTER I                                                                                 
STEROIDS AND DISEASE 
1.1 Steroid Overview 
 Steroids, non-polar small molecule hormones, are enzymatically derived from 
cholesterol and regulate metabolic processes through the endocrine system (Figure 1.1) 
[1]. These hormones are essential to proper physical development, sexual differentiation 
and maturation, and metabolic homeostasis. Steroids are produced mainly in the adrenal 
glands, placenta, and gonads and are separated into classes (progestogens, 
glucocorticoids, mineralocorticoids, androgens and estrogens) based on their metabolic 
functions.  
Progestogens, glucocorticoids, and mineralocorticoids are 21-carbon steroids 
which are mainly produced in the adrenal gland with increased progestogen production in 
the placenta. Progestogens, which include pregnenolone, progesterone, 17-
hydroxypregnenolone, and 17-hydroxyprogesterone, are precursors to all other steroids 
and have pro-gestational functions. The glucocorticoids (cortisol and cortisone) and 
mineralocorticoids (aldosterone, deoxycorticosterone, and corticosterone) are involved in 
glucose metabolism and mineral metabolism, respectively. The sex steroids are composed 
 2 
of the androgens and estrogens. The androgens include dehydroepiandrosterone, 
androstenedione, 5-androstenediol, testosterone, and dihydrotestosterone and are 
produced in the testes (males), ovaries (female), and adrenal gland (males and females). 
Testosterone is the major male sex steroid in circulation and is converted into 
dihydrotestosterone in the target tissues. While the androgens are the male sex hormones, 
the female sex hormones are the estrogens and include estrone, estradiol, and estriol. 
Abnormal production of these hormones can indicate various human diseases such as 
congenital metabolic defects, hyperplasia, and cancer. Accurate assessment of steroid 
levels is essential in determining possible adverse conditions in patients. Steroids that are 
commonly tested in the clinical laboratory include cortisol, aldosterone, 17-
hydroxyprogesterone, testosterone, estradiol, progesterone and androstenedione [1].  
1.1.1 Major Site of Steroid Production 
The adrenal glands are situated anteromedial to the kidneys and their major 
function is to produce small molecule hormones (Figure 1.2).  The adrenal gland has two 
sections, the cortex and the medulla. The cortex produces steroid hormones while the 
medulla produces catecholamines. The cortex is divided into three distinct zones known 
as the zona glomerulosa, the zona fasciculate, and the zona reticularis (Figure 1.3). The 
zona glomerulosa is the outer most zone of the adrenal gland and is the site of 
mineralocorticoid production (e.g. aldosterone) which is partially responsible for sodium 
and water homeostasis. The zona reticularis is the layer adjacent to the medulla where 
androgens (sex hormones) are produced and the major site of androgen production for 
 3 
females. The zona fasciculate is between the zona glomerulosa and the zona reticularis 
and is the major area of production for glucocorticoid steroids such as cortisol. 
 4 
 
Figure 1.1: Human Steroidogenesis Pathway. Reproduced from [2]. 
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Figure 1.2: Adrenal Glands 
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Figure 1.3: Labeled Microscope Picture of Cross-section Adrenal Gland. 
https://commons.wikimedia.org/wiki/File:Adrenal_gland_%28cortex%29.JPG made 
available under the Creative Commons CC0 1.0 Universal Public Domain Dedication  
  
 7 
Adrenal cells produce the steroids through various cytochrome P450 enzymes that 
catalyze the hydroxylation of pregnenolone into other constituent steroids. The primary 
enzymes needed for the final conversion for cortisol, cortisone, and aldosterone are 
cytochrome P450 11B1 (11β-hydroxylase in Figure 1.1), 11β-hydroxysteroid 
dehydrogenase type 1 and type 2, and cytochrome P450 11B2 (aldosterone synthase in 
Figure 1.1), respectively [2 3]. Once produced these steroids then need to be released into 
circulation to perform their specific functions. Aldosterone can freely circulate in the 
blood stream. However, cortisol and cortisone need to be protein bound due to the 
hydrophobicity of the compounds. The major binding protein is corticosteroid-binding 
globulin (CBG) also known as transcortin, while the minor binding protein is albumin. 
While the adrenal glands are the major site of steroid production overall, producing the 
mineralocorticoids and glucocorticoids, the primary site for androgen production in males 
is the testes. The testes have two main functions. The first function is production of male 
gametes (sperm) and the second function is as an endocrine organ producing testosterone. 
Once produced testosterone has to be protein bound for circulation and the major binding 
protein is sex-hormone binding globulin (SHBG) with a minor portion being bound by 
albumin. Unlike cortisol and aldosterone, testosterone is not the active hormone. Non-
protein bound testosterone is taken up by the cells and is converted to dihydrotestosterone 
by the 5α-reductase enzyme giving rise to the active androgen hormone.  
1.1.2 Steroid Regulation 
The hypothalamus-pituitary-adrenal axis (HPA axis) mainly regulates the 
production of cortisol [4]. The hypothalamus produces a tropic peptide hormone called 
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corticotropin-releasing hormone (CRH) which crosses over to the anterior portion of the 
pituitary gland. In response to the CRH, the anterior pituitary releases the tropic peptide 
hormone adrenocorticotropin (ACTH) into the blood stream where it interacts with the 
adrenal cortex portion of the adrenal gland.  Cortisol is produced in response to this 
stimulation and released from the adrenal cortex where it has various downstream effects 
(Table 1.1). Cortisol has negative feedback to the hypothalamus and the pituitary glands 
and is often an area of disruption for diseases. 
The hypothalamus-pituitary-gonadal axis (HPG axis) mainly regulates the 
production of sex hormones. The hypothalamus produces a peptide hormone called 
gonadotrophin-releasing hormone (GnRH) in a pulse fashion which crosses to the 
anterior portion of the pituitary gland. In response to the GnRH, the anterior pituitary 
releases the peptide hormones release follicle-stimulating hormone (FSH) and luteinizing 
hormone (LH) into the blood stream where for males it stimulates the leydig cells in the 
testes to produce testosterone.  FSH directly promotes spermatogenesis through the 
sertoli cells in the testes. Testosterone has a direct negative feedback of GnRH, LH and 
FSH production through the hypothalamus and pituitary glands.  
Aldosterone has some similar regulation under ACTH but is primarily controlled 
through the renin-angiotensin-aldosterone system (RAAS) and potassium concentrations. 
RAAS is a multistep process where a decrease in renal perfusion, a decrease in sodium 
concentration in the nephron, or a signal from the sympathetic nervous system causes the 
release of renin from the juxtaglomerular kidney cells. Renin then cleaves a peptide 
known as angiotensin I from the protein angiotensinogen produced from the liver. 
Angiotensin I is further cleaved by angiotensin-converting enzyme (ACE) into 
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angiotensin II. Angiotensin II then acts on the adrenal gland to release aldosterone and 
other target tissues to increase water absorption and potassium excretion (Figure 1.4).  
1.1.3 Steroids and Diseases 
There are many diseases associated with steroids due to their far reaching effects. 
A few examples follow with the first being Cushing’s syndrome. Cushing’s syndrome is 
caused from chronic excess of cortisol. Symptoms of Cushing’s syndrome or 
hypercortisolism include increased deposits of visceral fat, impaired healing, increased 
infections, and thinning fragile skin. The primary causes of hypercortisolism typically 
stem from cancers and hyperplasias. Pituitary-dependent Cushing’s syndrome is 
generally caused by an excessive secretion of ACTH and accounts for about 80% of 
Cushing’s syndrome. Other cancers can cause ACTH and CRH to be produced, causing 
an increase in cortisol. Additionally, adenomas and carcinomas of the adrenal gland have 
been known to directly secrete excess cortisol. Secondarily, excess cortisol treatment can 
also trigger Cushing’s syndrome. Each of these requires a specific testing algorithm to 
identify as well as imaging to help diagnose. Genetic defects can also create enzymatic 
blocks in steroid synthesis which lead to excess cortisol. However, these are generally 
multifactorial due to increases in multiple steroids. Often these are seen in early 
childhood, as soon as the first days of life, but they may surface later due to partial rather 
than total loss of gene function. Congenital adrenal hyperplasia (CAH) is an example of 
this, as well as some mitochondrial diseases.  
 10 
 
Figure 1.4: Detailed Control Mechanisms for RAAS. 
By A. Rad (me) - Own work, CC BY-SA 3.0, 
https://commons.wikimedia.org/w/index.php?curid=549506 
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Aldosterone is another common target and has a role in diseases such as CAH. 
These individuals are marked with a salt-wasting phenotype due to lack of aldosterone 
production. Additionally, people who have hyperaldosteronism, usually due to adrenal 
hyperplasia’s, have high blood pressure which causes damage to other organs such as the 
heart, liver, kidneys, and brain.  
In order to accurately and precisely diagnose these diseases multiple steroids 
including cortisol would be useful. The current methods capable of measuring multiple 
steroids at a single time use liquid chromatography-mass spectrometry (LC-MS) 
technology. 
1.2 Immunoassays vs. LC-MS/MS 
Analytical steroid measurement was first achieved through various types of 
immunoassays (IA). One of the first major advancements for endocrinological testing 
was Yalow and Berson’s creation of radioIA [1].  This technique made inexpensive 
quantitative testing for steroids possible.  Later, radioIA were adapted by replacing the 
radioligands with non-isotopic ligands creating IA and automated IA [1]. IA are quick 
and require no pre-extraction steps and are now the most common form of steroid 
hormone analysis within the laboratory [1]. However, the heterophilic antibodies often 
tend to produce false positives [6] or false negatives and allow for overestimation [7]. 
The format of the IA allows for testing of only a single steroid at a time which means 
multiple tests must be performed if more than one steroid is to be tested [8]. Additionally, 
these steroid methodologies are often inaccurate due to antibody cross reactivities, a lack 
of sensitivity, and improper validation [9].  
 12 
Table 1.1. Biological Effects of Cortisol (modified from [5]). 
Hormone Biological effects 
Cortisol 
Protein nitrogen catabolism increased 
Gluconeogenesis 
Increased blood glucose concentration 
Decreased glucose tolerance 
Increased liver glycogen 
Increased liver glycogenolysis 
Decreased peripheral uptake and 
utilization of glucose 
Decreased synthesis of acid-sulfated 
mucopolysaccharides 
Fat synthesis and redistribution 
Cellular or tissue effects 
Anti-inflammatory 
Dissolution of lymphoid tissue 
Lymphopenia 
Eosinopenia 
Increased erythropoiesis 
Alteration of cellular permeability, 
especially decreased membrane 
permeability to water 
Increased gastric (HCl and pepsin) 
secretion 
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Gas chromatography mass spectrometry (GC-MS) has also been used to quantify 
steroids [10 11]. This methodology combines chromatographic separation with mass 
spectrometry detection which affords high specificity and when an appropriate internal 
standard is used the variation from the extensive sample preparation is reduced [10]. GC-
MS requires the steroids to be volatile which entails derivation and high temperature 
evaporation [10]. This extends the time required for sample preparation and reduces the 
sensitivity due to thermal degradation of the steroids. Hence, GC-MS is highly laborious 
and has poor sensitivity and high costs [9]. 
Recently, LC-MS/MS has been leveraged for steroid analysis to eliminate the 
inconsistencies and disadvantages found in other methodologies. LC-MS/MS is quickly 
becoming the preferred testing method for steroid determination due to its higher 
sensitivity and increased specificity [1 12] 
Liquid chromatography tandem mass spectrometry has been chosen as the bench 
mark/’gold standard’ for many important clinical assays due to the sensitivity and 
specificity the methodology imparts to clinically relevant analytes such as 
immunosuppressants [13], testosterone [14], and HbA1c [15].  
1.3 References 
1. Kulle AE, Welzel M, Holterhus PM, Riepe FG. Principles and clinical applications of 
liquid chromatography - tandem mass spectrometry for the determination of adrenal and 
gonadal steroid hormones. J Endocrinol Invest 2011;34(9):702-8 doi: 10.3275/7843. 
 14 
2. Drelon C, Berthon A, Mathieu M, Martinez A, Val P. Adrenal cortex tissue 
homeostasis and zonation: A WNT perspective. Mol Cell Endocrinol 2015;408:156-64 
doi: 10.1016/j.mce.2014.12.014. 
3. Andrew R, Homer NZ. Mass spectrometry and its evolving role in assessing tissue 
specific steroid metabolism. Biochem Soc Trans 2016;44(2):645-51 doi: 
10.1042/bst20150234. 
4. Burtis CA, Bruns DE, Sawyer BG, Tietz NW. Tietz fundamentals of clinical chemistry 
and molecular diagnostics. Seventh edition. ed. 
5. McPherson RA, Pincus MR. Henry's clinical diagnosis and management by laboratory 
methods. Edition 23. ed. 
6. Fingerhut R. False positive rate in newborn screening for congenital adrenal 
hyperplasia (CAH)-ether extraction reveals two distinct reasons for elevated 17alpha-
hydroxyprogesterone (17-OHP) values. Steroids 2009;74(8):662-5 doi: 
10.1016/j.steroids.2009.02.008. 
7. Carvalho VM. The coming of age of liquid chromatography coupled to tandem mass 
spectrometry in the endocrinology laboratory. J Chromatogr B Analyt Technol Biomed 
Life Sci 2012;883-884:50-8 doi: 10.1016/j.jchromb.2011.08.027. 
8. Soldin SJ, Soldin OP. Steroid hormone analysis by tandem mass spectrometry. Clin 
Chem 2009;55(6):1061-6 doi: 10.1373/clinchem.2007.100008. 
9. Kushnir MM, Rockwood AL, Roberts WL, Yue B, Bergquist J, Meikle AW. Liquid 
chromatography tandem mass spectrometry for analysis of steroids in clinical 
laboratories. Clin Biochem 2011;44(1):77-88 doi: 10.1016/j.clinbiochem.2010.07.008. 
 15 
10. Vogeser M, Parhofer KG. Liquid chromatography tandem-mass spectrometry (LC-
MS/MS)--technique and applications in endocrinology. Exp Clin Endocrinol Diabetes 
2007;115(9):559-70 doi: 10.1055/s-2007-981458. 
11. Steen G, Tas AC, Ten Noever De Brauw MC, Drayer NM, Wolthers BG. The early 
recognition of the 21-hydroxylase deficiency variety of congenital adrenal hyperplasia. 
Clin Chim Acta 1980;105(2):213-24  
12. McDonald JG, Matthew S, Auchus RJ. Steroid profiling by gas chromatography-mass 
spectrometry and high performance liquid chromatography-mass spectrometry for 
adrenal diseases. Horm Cancer 2011;2(6):324-32 doi: 10.1007/s12672-011-0099-x. 
13. Aucella F, Lauriola V, Vecchione G, Tiscia GL, Grandone E. Liquid 
chromatography–tandem mass spectrometry method as the golden standard for 
therapeutic drug monitoring in renal transplant. Journal of Pharmaceutical and 
Biomedical Analysis 2013;86(0):123-26 doi: 
http://dx.doi.org/10.1016/j.jpba.2013.08.001. 
14. Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Utility, Limitations, and Pitfalls in 
Measuring Testosterone: An Endocrine Society Position Statement. Journal of Clinical 
Endocrinology & Metabolism 2007;92(2):405-13 doi: 10.1210/jc.2006-1864. 
15. Jeppsson JO, Kobold U, Barr J, et al. Approved IFCC reference method for the 
measurement of HbA1c in human blood. Clin Chem Lab Med 2002;40(1):78-89 doi: 
10.1515/cclm.2002.016. 
 
 
 16 
CHAPTER II                                                                                      
LIQUID CHROMATOGRAPHY-TANDEM MASS 
SPECTROMETRY METHOD DEVELOPMENT AND 
VALIDATION 
 
2.1 Introduction to Liquid Chromatography-Tandem Mass Spectrometry 
2.1.1 Liquid Chromatography-Tandem Mass Spectrometry in the Clinical Laboratory 
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is a high 
complexity analytical technique which has transitioned from the research area to the 
clinical laboratory and has greatly changed the clinical chemistry landscape especially in 
areas such as newborn screening and endocrinology [1-3]. LC-MS/MS became 
entrenched in the clinical laboratory when it was used to improve the accuracy of 
immunosuppressants measurement over previous techniques [4]. During the early years, 
challenging low molecular weight compounds were the major targets (e.g. vitamin D 
metabolites [5] and steroids [6]).  Analytes such as these require a higher sensitivity and 
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specificity than can be afforded by many immunoassays (Figure 2.1). Many clinical 
laboratories, including ours, are using LC-MS/MS for the routine analysis of proteins [7] 
and metabolic profiling [8]. The focus of this dissertation will be small molecule analysis 
by LC-MS/MS. The strengths, weaknesses, opportunities and threats which are referred 
to as SWOT by [1] of this technology are summarized in Table 2.1.  
Triple quadrupole MS instruments are the “gold standard” for small molecule LC-
MS/MS analysis in clinical laboratories [9]. For small molecule quantitation, they possess 
lower resolution than other MS analyzers; however, triple quadrupole instruments 
provide the sensitivity, selectivity, and quantitative performance that is particularly suited 
for most clinical assays (Table 2.2). 
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Figure 2.1: Dynamic Range of Low Molecular Weight Biomarkers in Adult Human 
Serum. Shown are mean and ranges. Reproduced from [1]. 
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Table 2.1: Analysis of LC-MS Strength, Weakness, Opportunities, and Threats (SWOT) 
in Clinical Diagnostics. Adapted from [1] and reproduced from [10]. 
Strengths 
High Sensitivity 
High Selectivity 
High speed of development at low costs of new 
assays compared to IVD immunoassays 
Low costs per sample in terms of reagents 
Can measure multiple analytes simultaneously 
Versatility 
Near reference methodology in routine setting 
Matrix independency (saliva, CSF, urine, etc.) 
Compatible with automated sample handling 
configurations 
Weaknesses 
High instrument costs 
Batch (non random-access) operation 
Need for highly skilled personnel for method 
development, validation, operation and 
troubleshooting 
Lack of clearly defined quality regulations 
Limited sample throughput in conventional 
set–up 
Absence or limited availability of CE/IVD 
approved reagent-kits 
MS vendors have limited IVD requirements 
Opportunities 
Progress towards more user-friendly 
instruments (with integration of all components 
into a single system) 
Adoption of MS technology by major IVD 
companies 
Broader availability of CE/IVD approved kits 
for LC-MS/MS analysis 
Quantitative measurement of clinical peptides 
and proteins 
Metabolic profiling 
Threats 
New instruments are developed rapidly 
Growing difficulty finding skilled and 
experienced technicians 
Lack of commitment from major IVD 
companies 
Regulatory bodies applying restrictions on 
using home-brew assays for diagnostic 
purposes 
Competition from innovations in 
immunoassays or from the introduction of new 
technologies 
 
 20 
Table 2.2: Comparison of the General Features of Single and Triple Quad Instruments 
with Quadrupole-Time-Of-Flight (Q-TOF) and Linear Ion Trap Orbitrap (LTQ-orbitrap). 
Reproduced from [9]. 
 Single Quad Triple Quad Q-TOF LTQ-Orbitrap 
Sensitivity + +++ +++ +++ 
Selectivity + +++ +++ +++ 
Resolution + + +++ +++ 
Performance for 
quantification 
++ +++ ++ ++ 
Identification of 
target compounds 
++ +++ +++ +++ 
Identification of 
unknown 
compounds 
+ ++ +++ +++ 
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2.1.2 Liquid Chromatography-Triple Quadrupole Mass Spectrometry  
LC-MS/MS samples require processing which is outlined in Figure 2.2. First 
obtain a sample from the patient. Blood, serum, plasma and urine are most common. 
Samples are then centrifuged, except whole blood which is used for intracellular analytes 
such as the immunosuppressants, to separate cells or sediment from plasma, serum, or 
urine. One of the major issues with LC-MS/MS is ion suppression caused by interfering 
ions and proteins. To improve the overall analyte signal, samples need to have these 
interfering agents removed. This is accomplished using sample preparation techniques 
outlined in Figure 2.3. Next, sample are applied to a LC system that further purifies and 
separates the analytes based on their chemical properties and relies on partitioning of the 
analyte between a stationary phase (i.e. analytical column) and a mobile phase. Stationary 
phase selection is dependent on the physical and chemical properties of the analyte. There 
are different modes of interaction which are categorized as adsorption chromatography, 
ion-exchange chromatography, size-exclusion chromatography, hydrophilic interaction 
chromatography (HILIC), or mixed-mode where more than one interaction is occurring at 
a time. The analyte-of-interest is directed to the ion source of the MS where gaseous ions 
are created through evaporation and ionization. For most methods, this is achieved by 
either using atmospheric pressure chemical ionization (APCI) or heated electrospray 
ionization (HESI) though recently atmospheric pressure photoionization (APPI) has 
become popular for steroids. APCI evaporates the compounds with dry gas and high 
temperatures then ionizes the gaseous compounds using a high voltage discharge from a 
charged corona needle before entering into the MS. HESI uses a slightly different 
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approach to ionization and imparts charge across the solvent surface while droplets are 
formed prior to evaporation and introduction into the MS. HESI is generally preferred for 
most applications because it is less likely to fragment the ions before entering the MS. 
After the gas phase ion formation, the ions are compressed into a beam upon entering the 
MS. The ion beam then enters the first quadrupole (Q1), where mass selection of the 
charged precursor ion is performed. Then the ion beam enters the collision cell (Q2), 
where the precursor ion is accelerated in the presence of inert gas molecules causing 
collisions that fragment the molecule giving rise to product ions. A second selection is 
performed in third quadrupole (Q3) identifying the ion which will strike the electron 
multiplier to be detected. The final result is a chromatogram with ion intensity on the x-
axis and time on the y-axis. 
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Figure 2.2: Illustration of the Steps Involved in LC-MS/MS Analysis. (a) Blood tubes are 
first centrifuged with the resulting supernatant (plasma or serum) transferred to a 
centrifuge tube. Plasma or serum is then further purified by (b) protein precipitation, (c) 
liquid-liquid extraction, (d) solid-phase extraction, derivatization, or online sample clean-
up prior to injection onto the LC system. (e) Chromatographic separation is then 
performed on the analytical column before (f) evaporation and ionization of the analyte in 
the ion source and (g) being introduced through the ion tube into the MS. The (h) first 
quadrupole selects the precursor ion of the desired analyte, while the (i) second 
quadrupole fragments that ion by collision with an inert gas. The (j) third quadrupole then 
selects the product ion that is then (k) detected and quantified.   Reproduced from [10]. 
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2.1.3 LC-MS/MS Method Development 
The three major components of LC-MS/MS method development are MS and LC 
optimization and sample preparation procedures. They proceed in that order because the 
MS parameters can be optimized independent of the LC parameters, which can be 
optimized independent of sample preparation procedures, but the reverse is not true. 
Initial optimization of the MS and LC parameters is performed using analytes in solvent. 
Since the only detector attached to the LC system is a MS, optimizing the MS first allows 
the detection of the analyte. Next LC optimization is performed which allows us to 
observe how well the analytical column retains our analyte and chromatographically 
resolves any potential interference. Finally, sample preparation is optimized to purify 
analyte from any interferences that could not be resolved by the LC-MS/MS platform, 
and to provide a cleaner extract for injection. Ideally, the final composition of the extract 
is optimized to match the initial mobile phase conditions used for the LC separation. 
Once the initial optimization is performed a second round of optimization if performed. 
First the MS conditions are optimized to the LC eluting conditions for the analyte. 
Secondly, the LC conditions are modified to enhance the separation and peak shape of 
real extracted patient samples. Sample preparation conditions are not usually revisited 
unless the assay fails the mixing study in the initial phase of validation. 
2.1.3.1 Mass Spectrometry Optimization 
This is generally the first step in LC-MS/MS method development and it involves 
preparation of a solvent based solution containing the analyte at a relatively high 
concentration (typically 1 µg/mL). This solution is then infused to the MS using a syringe 
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pump. The MS is typically set to scan mode at start so that the expected peak is first 
identified. After locating the expected peak corresponding to the molecular weight of the 
analyte, the ion source conditions are optimized. Ion source conditions depend on the 
choice of ion source, HESI or APCI. In HESI, the ion source parameters that can be 
optimized are spray voltage, capillary temperature, vaporizer temperature, ion sweep gas, 
sheath gas, and auxiliary gas. In APCI, the method of ionization is different so a corona 
needle voltage is used instead of spray voltage. The ideal parameter combination reduces 
background noise while maximizing ionization of the analyte molecules.  
Once ion source parameters are optimized, the MS mode is changed from 
scanning to product ion monitoring. In this mode, an automatic optimization is used 
initially. The automatic optimization requires the precursor mass/charge (m/z) ion then 
identifies the most abundant product m/z ions and reports an optimized collision energy. 
These are confirmed through manual tuning of the instrument. The purpose is to select a 
product ion in Q3 with the highest sensitivity to monitor for quantification, and a second 
product ion for qualification.  
 When ionization is an issue compounds can be modified through chemical 
processes. Steroids have three major analytical issues which are ionization efficiency, 
matrix effects, and isobaric interferences and compounds such as pregnenolone, 17-
hydroxypregnenolone, and dehydroepiandrostenedione (DHEA) can be particularly 
troublesome in these regards. These steroids are particularly difficult to ionize using 
normal LC-MS/MS ionization techniques, HESI or APCI. A method that can overcome 
these ionization issues is chemical derivation. Based on the structure and functional 
groups of steroids, the chemical derivations usually utilize the keto or hydroxyl groups to 
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add chargeable moieties allowing for improved ionization [11]. Schiff base type reactions 
can attach these moieties to keto groups. These moieties can carry charged groups 
(nitrogen-Girard P and T) or groups that are easily ionized such as hydroxyl 
(hydroxylamine), carboxylic acid (carboxymethoxylamine), or sulfur groups (p-
toluenesulfonylhydrazone). The compounds capable of derivatizing the hydroxyl groups 
(2-fluoro-1-methylpyridinium p-toluenesulfonate and dansyl chloride) have similar 
motifs [11]. In addition to the improved ionization, these chemical additions can improve 
chromatographic separation of isobaric interferences and substances causing matrix 
effects. The additional moieties can also change the parent ion fragmentation pattern 
yielding high abundance product ions that distinguish between isobars. The 
disadvantages are three folds: extra labor time is needed to perform the assays; precision 
may be compromised dues to extra steps introduced; accuracy could be reduced due to 
the possible hydrolysis of conjugates under the derivatization conditions [12]. One should 
consider the steroid panel components and the clinical needs to determine if 
derivatization is necessary. 
During the development process, experiments were performed to determine the 
effectiveness of different derivation compounds. These derivation compounds (Figure 
2.3) all used Schiff base type chemistry to add on chemical moieties (Figure 2.4-5). The 
experiment consisted of 3 mL of steroid at 6.3 µmol/L which had 75 µL of the derivation 
reagent added. The steroids tested included pregnenolone, cortisol, cortisone, aldosterone, 
testosterone, 17-hydroxyprogesterone, and 11-deoxycortisol. The reaction was conducted 
at room temperature and was not allowed to proceed past 1 hour in keeping with the time 
restraints of the clinical laboratory. Samples (500 µL) were removed at 15 min 
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increments, spiked with 10 µL of reserpine (10 mg/mL) as an ionization control then 
directly infused onto the MS. Responses were recorded for the steroid at all expected 
molecular weights and for reserpine. The ratio of steroid response to the reserpine 
response was compared to the 0 time baseline. Ionization increases were compared to the 
values at time zero to determine the largest improvement in ionization and the percent 
coefficient of variation was determined to identify the best derivation reagent. The data is 
listed below in Table 2.3-16.  
To conclude this section, the overall best derivation reagent was the QAO reagent 
from AB Sciex. The most likely cause is the charged motif on the reagent. Due to this 
motif, it is changed once the reaction is complete and does not require the mass 
spectrometer to charge the molecule. However, it is also the most expensive. The second 
best based on ionization improvements and consistency was the hydroxylamine. The 
other reagents worked well with specific steroids but were not ideal for general use. The 
major issue with the derivation was the number of isomers created for steroids with 
multiple keto-groups and the derivation process increased the amount of isobaric 
compounds and the likelihood of cross talk among the mass spectrometer steroid 
channels. In essence, the derivation process increased the complexity of the sample which 
is the opposite of the sample preparation goal. However, derivation was used in certain 
cases where there was a strong need to increase the ionization of a steroid (e.g. 
pregnenolone). 
  
 28 
 
 
Figure 2.3: Possible Derivation Reagents. 
The name of the compounds is as follows A. Hydroxylamine B. Methoxyamine C. 
Ethoxyamine D. QAO reagent from AB Sciex and E. 2-Hydrazinopyridine 
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Figure 2.4: Schiff Base Reaction with an Imine and Hydrazine 
UC Davis ChemWiki is licensed under a Creative Commons Attribution-
Noncommercial-Share Alike 3.0 United States License 
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Figure 2.5: Schiff Base Reaction Mechanism 
UC Davis ChemWiki is licensed under a Creative Commons Attribution-
Noncommercial-Share Alike 3.0 United States License 
Step1 
Step2 
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Table 2.3: Pregnenolone Derivations Normalized to Reserpine Ionization 
Time 
Point Pregnenolone Hydroxylamine 1   MW 332 
 
mean std Increase %cv 
0 3.4E-02 2.3E-02 
 
68% 
15 1.5E-01 3.5E-02 433% 24% 
30 3.4E-01 3.8E-02 999% 11% 
45 2.1E-01 5.3E-02 625% 25% 
60 2.1E-01 2.8E-02 617% 14% 
   
 
 
 
Pregnenolone Methoxyamine 1   MW 346 
 
mean std Increase %cv 
0 4.1E-03 2.5E-03 
 
60% 
15 1.2E-02 3.7E-03 287% 31% 
30 2.9E-02 2.8E-03 702% 10% 
45 4.1E-02 2.1E-02 994% 50% 
60 2.9E-02 1.0E-02 703% 35% 
   
 
 
 
Pregnenolone Ethoxyamine 1   MW 360 
 
mean std Increase %cv 
0 6.1E-03 7.7E-04 
 
13% 
15 1.9E-02 4.0E-03 312% 21% 
30 2.7E-02 2.6E-03 444% 10% 
45 3.0E-02 1.3E-02 500% 42% 
60 1.1E-01 1.4E-01 1739% 129% 
   
 
 
 
Pregnenolone 2-Hydrazinopyridine 1   MW 408 
 
mean std Increase %cv 
0 3.4E-03 5.0E-04 
 
15% 
15 8.2E-03 1.7E-03 238% 20% 
30 1.2E-02 5.2E-04 365% 4% 
45 2.4E-02 1.1E-02 696% 45% 
60 2.2E-02 1.7E-03 656% 8% 
   
 
 
 
Pregnenolone QAO Reagent 1   MW 432 
 
mean std Increase %cv 
0 6.48E-03 2.41E-03 
 
37% 
15 6.36E-02 2.24E-02 982% 35% 
30 9.00E-02 2.58E-02 1388% 29% 
45 1.12E-01 1.25E-02 1730% 11% 
60 1.18E-01 1.77E-02 1817% 15% 
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Table 2.4: Cortisol Single Keto-group Derivations Normalized to Reserpine Ionization 
Time 
Point 
Cortisol Hydroxylamine 1   MW 378 
mean std Increase %cv 
0 6.64E-02 4.75E-02 
 
72% 
15 2.19E-01 1.35E-01 330% 61% 
30 1.30E-01 5.03E-02 195% 39% 
45 1.88E+00 2.95E+00 2826% 157% 
60 1.09E-01 7.44E-02 164% 68% 
 
    
 
Cortisol Methoxyamine 1   MW 392 
 
mean std Increase %cv 
0 2.79E-02 5.98E-03 
 
21% 
15 1.17E-01 3.51E-02 418% 30% 
30 1.25E-01 2.89E-02 446% 23% 
45 8.80E-02 3.97E-02 315% 45% 
60 1.01E-01 1.67E-02 360% 17% 
 
    
 
Cortisol Ethoxyamine 1   MW 406 
 
mean std Increase %cv 
0 4.57E-02 2.73E-02 
 
60% 
15 1.12E-01 4.36E-02 244% 39% 
30 1.33E-01 5.80E-02 290% 44% 
45 9.03E-02 5.50E-02 198% 61% 
60 1.27E-01 1.07E-01 278% 84% 
 
    
 
Cortisol 2-Hydrazinopyridine 1   MW 454 
 
mean std Increase %cv 
0 4.87E-03 4.07E-03 
 
84% 
15 6.89E-03 1.68E-03 141% 24% 
30 1.07E-02 9.61E-04 220% 9% 
45 1.66E-02 1.07E-03 341% 6% 
60 2.10E-02 1.26E-03 431% 6% 
 
    
 
Cortisol QAO Reagent 1   MW 477 
 
mean std Increase %cv 
0 2.14E-02 3.70E-03 
 
17% 
15 4.15E-01 5.96E-02 1938% 14% 
30 3.94E-01 1.17E-01 1840% 30% 
45 4.15E-01 1.58E-01 1942% 38% 
60 3.79E-01 1.16E-01 1773% 31% 
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Table 2.5: Cortisol Double Keto-group Derivations Normalized to Reserpine Ionization 
Time 
Point 
Cortisol Hydroxylamine 2   MW 393 
mean std Increase %cv 
0 4.47E-03 4.80E-03 
 
107% 
15 2.20E-03 8.87E-04 49% 40% 
30 2.97E-03 2.55E-03 66% 86% 
45 6.54E-02 1.13E-01 1465% 172% 
60 2.89E-03 2.21E-03 65% 77% 
 
    
 
Cortisol Methoxyamine 2   MW 421 
 
mean std Increase %cv 
0 2.16E-03 3.33E-03 
 
154% 
15 1.80E-03 1.26E-03 83% 70% 
30 2.62E-03 7.37E-04 121% 28% 
45 1.93E-03 9.90E-04 89% 51% 
60 2.20E-03 1.01E-03 102% 46% 
 
    
 
Cortisol Ethoxyamine 2   MW 449 
 
mean std Increase %cv 
0 1.18E-03 4.91E-04 
 
42% 
15 1.78E-03 3.78E-04 151% 21% 
30 3.04E-03 1.21E-03 257% 40% 
45 1.70E-03 6.96E-04 144% 41% 
60 2.07E-03 1.81E-03 176% 87% 
 
    
 
Cortisol 2-Hydrazinopyridine 2   MW545 
 
mean std Increase %cv 
0 2.04E-03 1.00E-03 
 
49% 
15 1.97E-03 3.83E-04 97% 19% 
30 1.90E-03 5.71E-04 93% 30% 
45 1.90E-03 3.73E-04 93% 20% 
60 1.95E-03 8.43E-05 95% 4% 
 
    
 
Cortisol QAO Reagent 2   MW 296 
 
mean std Increase %cv 
0 4.79E-02 5.85E-03 
 
12% 
15 6.80E-02 1.07E-02 142% 16% 
30 6.48E-02 1.75E-02 135% 27% 
45 7.64E-02 2.34E-02 159% 31% 
60 7.85E-02 2.14E-02 164% 27% 
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Table 2.6: Cortisone Single Keto-group Derivations Normalized to Reserpine Ionization 
Time 
Point 
Cortisone Hydroxylamine 1   MW 376 
mean std Increase %cv 
0 4.15E-02 7.41E-03 
 
18% 
15 2.05E-01 2.58E-02 493% 13% 
30 3.02E-01 4.53E-02 727% 15% 
45 2.64E-01 7.09E-02 637% 27% 
60 2.47E-01 6.99E-02 594% 28% 
 
    
 
Cortisone Methoxyamine 1   MW 390 
 
mean std Increase %cv 
0 2.75E-02 3.67E-03 
 
13% 
15 1.31E-01 3.64E-02 476% 28% 
30 1.63E-01 5.06E-02 591% 31% 
45 1.88E-01 3.31E-02 684% 18% 
60 2.86E-01 1.92E-01 1041% 67% 
 
    
 
Cortisone Ethoxyamine 1   MW 404 
 
mean std Increase %cv 
0 3.37E-02 1.54E-02 
 
46% 
15 1.82E-01 2.75E-02 539% 15% 
30 2.48E-01 1.72E-01 735% 69% 
45 2.84E-01 6.58E-02 844% 23% 
60 2.46E-01 4.24E-02 729% 17% 
 
    
 
Cortisone 2-Hydrazinopyridine 1   MW 452 
 
mean std Increase %cv 
0 3.06E-03 1.94E-04 
 
6% 
15 8.13E-03 2.13E-03 265% 26% 
30 1.58E-02 3.10E-03 518% 20% 
45 2.29E-02 2.67E-03 748% 12% 
60 3.16E-02 5.09E-03 1033% 16% 
 
    
 
Cortisone QAO Reagent 1   MW 475 
 
mean std Increase %cv 
0 2.22E-02 5.20E-03 
 
23% 
15 3.95E-01 5.00E-02 1781% 13% 
30 3.84E-01 1.03E-01 1730% 27% 
45 3.98E-01 1.45E-01 1792% 36% 
60 3.64E-01 1.04E-01 1637% 29% 
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Table 2.7: Cortisone Double Keto-group Derivations Normalized to Reserpine Ionization 
Time 
Point 
Cortisone Hydroxlamine 2   MW 391 
mean std Increase %cv 
0 1.95E-03 3.83E-04 
 
20% 
15 1.97E-03 5.15E-04 101% 26% 
30 3.17E-03 7.95E-04 163% 25% 
45 2.94E-03 1.21E-03 151% 41% 
60 2.65E-03 1.09E-03 136% 41% 
     
 
Cortisone Methoxyamine 2   MW 419 
 
mean std Increase %cv 
0 6.26E-04 7.51E-04 
 
120% 
15 3.00E-03 1.43E-03 480% 48% 
30 3.86E-03 1.90E-03 616% 49% 
45 5.78E-03 1.94E-03 922% 34% 
60 8.00E-03 5.06E-03 1278% 63% 
     
 
Cortisone Ethoxyamine 2   MW 447 
 
mean std Increase %cv 
0 1.09E-03 4.12E-04 
 
38% 
15 4.18E-03 1.21E-03 384% 29% 
30 6.09E-03 5.30E-03 560% 87% 
45 1.44E-02 9.74E-03 1318% 68% 
60 9.06E-03 2.08E-03 832% 23% 
     
 
Cortisone 2-Hydrazinopyridine 2   MW 543 
 
mean std Increase %cv 
0 9.50E-04 1.36E-04 
 
14% 
15 1.05E-03 3.21E-04 111% 31% 
30 1.23E-03 2.39E-04 129% 20% 
45 1.32E-03 2.67E-04 139% 20% 
60 1.49E-03 3.13E-04 157% 21% 
     
 
Cortisone QAO Reagent 2   MW 295 
 
mean std Increase %cv 
0 2.78E-01 2.15E-02 
 
8% 
15 3.59E-01 5.58E-02 129% 16% 
30 3.05E-01 9.04E-02 110% 30% 
45 3.17E-01 1.06E-01 114% 34% 
60 3.05E-01 8.61E-02 110% 28% 
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Table 2.8: Cortisone Triple Keto-group Derivations Normalized to Reserpine Ionization 
Time 
Point 
Cortisone Hydroxylamine 3   MW 406 
mean std Increase %cv 
0 6.66E-03 6.30E-03 
 
95% 
15 6.27E-03 6.96E-03 94% 111% 
30 3.12E-03 3.06E-03 47% 98% 
45 1.71E-03 1.39E-03 26% 81% 
60 1.22E-03 1.34E-03 18% 110% 
     
 
Cortisone Methoxyamine 3   MW 448 
 
mean std Increase %cv 
0 2.26E-04 6.36E-06 
 
3% 
15 3.65E-04 6.57E-05 162% 18% 
30 3.66E-04 1.18E-04 162% 32% 
45 3.18E-04 5.10E-05 141% 16% 
60 3.60E-04 1.75E-04 160% 48% 
     
 
Cortisone Ethoxyamine 3   MW 490 
 
mean std Increase %cv 
0 7.81E-04 3.99E-04 
 
51% 
15 8.43E-04 9.78E-05 108% 12% 
30 8.54E-04 4.38E-04 109% 51% 
45 8.74E-04 2.90E-04 112% 33% 
60 6.73E-04 8.90E-05 86% 13% 
     
 
Cortisone 2-Hydrazinopyridine 3   MW 634 
 
mean std Increase %cv 
0 9.38E-04 8.89E-05 
 
9% 
15 1.08E-03 1.68E-04 115% 16% 
30 1.05E-03 1.16E-04 112% 11% 
45 1.08E-03 1.15E-04 115% 11% 
60 1.12E-03 1.54E-04 120% 14% 
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Table 2.9: Aldosterone Single Keto-group Derivations Normalized to Reserpine 
Ionization 
Time 
Point 
Aldosterone Hydroxylamine 1  MW 376 
mean std Increase %cv 
0 4.33E-02 2.01E-02 
 
46% 
15 2.26E-01 1.77E-02 523% 8% 
30 3.97E-01 8.90E-02 918% 22% 
45 3.10E-01 3.64E-02 715% 12% 
60 3.45E-01 1.29E-01 797% 37% 
     
 
Aldosterone Methoxyamine 1  MW 390 
 
mean std Increase %cv 
0 2.65E-02 6.41E-03 
 
24% 
15 7.88E-02 1.50E-02 298% 19% 
30 1.04E-01 2.36E-02 392% 23% 
45 9.83E-02 2.18E-02 95% 22% 
60 1.05E-01 3.97E-02 107% 38% 
     
 
Aldosterone Ethoxyamine 1  MW 404 
 
mean std Increase %cv 
0 1.87E-02 1.08E-02 
 
58% 
15 7.92E-02 1.82E-02 424% 23% 
30 1.17E-01 2.90E-02 625% 25% 
45 1.04E-01 4.32E-02 559% 41% 
60 1.68E-01 6.10E-02 902% 36% 
     
 
Aldosterone 2-Hydrazinopyridine 1  MW 452 
 
mean std Increase %cv 
0 2.32E-03 1.42E-03 
 
61% 
15 5.34E-03 1.31E-03 230% 24% 
30 8.22E-03 2.03E-03 354% 25% 
45 1.83E-02 1.16E-02 788% 64% 
60 1.66E-02 1.92E-03 716% 12% 
     
 
Aldosterone QAO Reagent 1  MW 475 
 
mean std Increase %cv 
0 1.05E-02 5.76E-03 
 
55% 
15 6.26E-02 2.87E-02 599% 46% 
30 6.88E-02 1.74E-02 658% 25% 
45 7.31E-02 3.69E-03 698% 5% 
60 6.89E-02 1.58E-02 659% 23% 
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Table 2.10: Aldosterone Double Keto-group Derivations Normalized to Reserpine 
Ionization 
Time 
Point 
Aldosterone Hydroxlamine 2 MW 391 
mean std Increase %cv 
0 1.25E-03 4.11E-04 
 
33% 
15 3.87E-03 6.49E-04 309% 17% 
30 8.94E-03 2.39E-03 713% 27% 
45 6.70E-03 8.65E-04 535% 13% 
60 7.32E-03 3.40E-03 584% 46% 
     
 
Aldosterone Methoxyamine 2  MW 419 
 
mean std Increase %cv 
0 6.00E-04 2.08E-04 
 
35% 
15 2.76E-03 1.28E-03 460% 46% 
30 6.07E-03 2.57E-03 1012% 42% 
45 4.89E-03 1.50E-03 814% 31% 
60 5.69E-03 3.05E-03 948% 54% 
     
 
Aldosterone Ethoxyamine 2  MW 447 
 
mean std Increase %cv 
0 8.40E-04 4.31E-04 
 
51% 
15 3.76E-03 1.62E-03 448% 43% 
30 7.04E-03 3.08E-03 838% 44% 
45 6.32E-03 3.31E-03 753% 52% 
60 1.14E-02 3.74E-03 1358% 33% 
     
 
Aldosterone 2-Hydrazinopyridine 2  MW 543 
 
mean std Increase %cv 
0 6.76E-04 4.23E-04 
 
63% 
15 9.62E-04 1.36E-04 142% 14% 
30 1.01E-03 2.07E-04 150% 20% 
45 1.83E-03 1.10E-03 271% 60% 
60 1.45E-03 2.62E-04 214% 18% 
     
 
Aldosterone QAO Reagent 2 MW 295 
 
mean std Increase %cv 
0 4.92E-01 2.76E-01 
 
56% 
15 3.04E-01 5.32E-02 62% 17% 
30 3.01E-01 3.50E-02 61% 12% 
45 3.26E-01 1.42E-02 66% 4% 
60 3.32E-01 4.81E-02 67% 15% 
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Table 2.11: Aldosterone Triple Keto-group Derivations Normalized to Reserpine 
Ionization 
Time 
Point 
Aldosterone Hydroxylamine 3 MW 406 
mean std Increase %cv 
0 6.65E-04 4.83E-05 
 
7% 
15 4.86E-04 9.76E-05 73% 20% 
30 5.24E-04 7.63E-05 79% 15% 
45 3.54E-04 5.68E-05 53% 16% 
60 3.58E-04 7.62E-05 54% 21% 
     
 
Aldosterone Methoxyamine 3 MW 448 
 
mean std Increase %cv 
0 4.19E-04 3.37E-05 
 
8% 
15 3.79E-04 3.89E-05 90% 10% 
30 3.88E-04 1.10E-04 93% 28% 
45 3.40E-04 5.45E-05 81% 16% 
60 3.50E-04 1.50E-04 83% 43% 
     
 
Aldosterone Ethoxyamine 3 MW 490 
 
mean std Increase %cv 
0 6.35E-04 4.13E-04 
 
65% 
15 6.02E-04 1.31E-04 95% 22% 
30 7.11E-04 2.03E-04 112% 29% 
45 5.70E-04 2.41E-04 90% 42% 
60 9.56E-04 3.03E-04 151% 32% 
     
 
Aldosterone 2-Hydrazinopyridine 3 MW 634 
 
mean std Increase %cv 
0 1.30E-03 2.26E-04 
 
17% 
15 1.28E-03 1.98E-04 98% 15% 
30 1.23E-03 6.72E-05 94% 5% 
45 1.64E-03 5.61E-04 126% 34% 
60 1.31E-03 5.69E-05 100% 4% 
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Table 2.12: Testosterone Derivations Normalized to Reserpine Ionization 
Time 
Point 
Testosterone Hydroxylamine 1   MW 304 
mean std Increase %cv 
0 9.47E-02 3.08E-02 
 
33% 
15 3.48E-01 8.72E-02 367% 25% 
30 3.49E-01 5.05E-03 368% 1% 
45 6.65E-01 2.93E-01 702% 44% 
60 5.55E-01 2.90E-01 585% 52% 
     
 
Testosterone 2-Hydrazinopyridine 1   MW 380 
 
mean std Increase %cv 
0 9.04E-03 8.75E-03 
 
97% 
15 8.17E-03 1.61E-03 90% 20% 
30 1.22E-02 9.89E-04 135% 8% 
45 1.53E-02 2.44E-03 169% 16% 
60 2.14E-02 3.13E-03 237% 15% 
     
 
Testosterone QAO Reagent 1   MW 403 
 
mean std Increase %cv 
0 3.35E-02 2.95E-02 
 
88% 
15 3.10E-01 3.48E-02 925% 11% 
30 4.60E-01 9.76E-02 1371% 21% 
45 4.94E-01 1.28E-01 1474% 26% 
60 5.06E-01 5.76E-02 1507% 11% 
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Table 2.13: 17-Hydroxyprogesterone Single Keto-group Derivations Normalized to 
Reserpine Ionization 
Time 
Point 
17 OH Progesterone Hydroxylamine 1  MW 346 
mean std Increase %cv 
0 7.75E-02 2.06E-02 
 
27% 
15 2.36E-01 4.31E-02 305% 18% 
30 2.40E-01 6.02E-03 309% 3% 
45 4.29E-01 2.02E-01 553% 47% 
60 3.45E-01 1.54E-01 446% 45% 
     
 
17 OH Progesterone 2-Hydrazinopyridine 1  MW 422 
 
mean std Increase %cv 
0 6.11E-03 1.22E-03 
 
20% 
15 1.10E-02 4.87E-04 180% 4% 
30 1.76E-02 2.36E-04 289% 1% 
45 2.21E-02 3.63E-03 361% 16% 
60 3.07E-02 3.91E-03 502% 13% 
     
 
17 OH Progesterone QAO Reagent 1  MW 445 
 
mean std Increase %cv 
0 2.32E-02 4.20E-04 
 
2% 
15 3.11E-01 5.82E-02 1343% 19% 
30 3.54E-01 9.17E-02 1528% 26% 
45 2.81E-01 6.94E-02 1212% 25% 
60 2.34E-01 3.05E-02 1011% 13% 
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Table 2.14: 17-Hydroxyprogesterone Double Keto-group Derivations Normalized to 
Reserpine Ionization 
Time 
Point 
17 OH Progesterone Hydroxylamine 2  MW 361 
mean std  Increase %cv 
0 1.95E-03 3.62E-04   19% 
15 1.09E-02 6.96E-03 562% 64% 
30 1.31E-02 4.40E-04 672% 3% 
45 3.09E-02 1.07E-02 1586% 35% 
60 3.18E-02 2.01E-02 1632% 63% 
          
  17 OH Progesterone 2-Hydrazinopyridine 2  MW 513 
  mean std  Increase %cv 
0 4.34E-03 6.50E-04   15% 
15 4.20E-03 6.08E-06 97% 0% 
30 4.73E-03 2.09E-04 109% 4% 
45 4.79E-03 9.17E-04 110% 19% 
60 5.68E-03 7.38E-04 131% 13% 
          
  17 OH Progesterone QAO Reagent 2  MW 280 
  mean std  Increase %cv 
0 1.11E-02 1.05E-02   94% 
15 9.32E-02 1.21E-02 838% 13% 
30 2.31E-01 4.00E-02 2077% 17% 
45 3.44E-01 1.05E-01 3094% 30% 
60 4.40E-01 2.77E-02 3954% 6% 
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Table 2.15: 11-deoxycortisol Single Keto-group Derivations Normalized to Reserpine 
Ionization 
Time 
Point 
11 Deoxycortisol Hydroxylamine 1  MW 362 
mean std  Increase %cv 
0 6.80E-02 1.46E-02   21% 
15 1.93E-01 5.13E-02 284% 27% 
30 1.93E-01 6.53E-03 283% 3% 
45 3.61E-01 1.46E-01 531% 40% 
60 2.97E-01 1.50E-01 437% 50% 
          
  11 Deoxycortisol 2-Hydrazinopyridine 1  MW 438 
  mean std  Increase %cv 
0 5.04E-03 5.56E-04   11% 
15 8.13E-03 3.23E-04 161% 4% 
30 1.25E-02 2.88E-04 249% 2% 
45 1.59E-02 2.58E-03 315% 16% 
60 2.31E-02 5.00E-03 459% 22% 
          
  11 Deoxycortisol QAO Reagent 1  MW 461 
  mean std  Increase %cv 
0 1.67E-02 2.57E-03   15% 
15 3.11E-01 5.28E-02 1866% 17% 
30 4.62E-01 1.07E-01 2770% 23% 
45 4.57E-01 1.13E-01 2740% 25% 
60 4.96E-01 4.52E-02 2974% 9% 
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Table 2.16: 11-deoxycortisol Double Keto-group Derivations Normalized to Reserpine 
Ionization  
Time 
Point 
11 Deoxycortisol Hydroxylamine 2   MW 377 
mean std  Increase %cv 
0 1.43E-03 3.89E-04   27% 
15 1.46E-03 1.79E-04 102% 12% 
30 1.28E-03 1.12E-05 89% 1% 
45 2.34E-03 8.62E-04 163% 37% 
60 2.41E-03 1.14E-03 168% 47% 
          
  11 Deoxycortisol 2-Hydrazinopyridine 2  MW 529 
  mean std  Increase %cv 
0 1.29E-03 2.26E-04   18% 
15 1.27E-03 5.17E-05 99% 4% 
30 1.40E-03 8.79E-05 109% 6% 
45 1.39E-03 2.61E-04 108% 19% 
60 1.55E-03 2.12E-04 120% 14% 
          
  11 Deoxycortisol QAO Reagent 2  MW 288 
  mean std  Increase %cv 
0 1.31E-02 1.44E-02   110% 
15 1.29E-02 1.57E-03 98% 12% 
30 2.64E-02 3.22E-03 201% 12% 
45 3.69E-02 9.48E-03 281% 26% 
60 4.87E-02 3.73E-03 371% 8% 
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2.1.3.2 Liquid Chromatography Optimization 
Upon optimization of the MS conditions using solvent based solutions and 
creation of an MS method, development begins on the LC portion of the assay. There are 
two basic elements that need to be selected before optimization begins; the analytical 
column and mobile phases. It is simpler and faster to test different analytical columns 
than to test different mobile phases. Due to this, generic mobile phases with MS safe 
additives (i.e. volatile) are used at the start. Commonly, water with 0.1% formic acid for 
mobile phase A and methanol for mobile phase B. The columns are tested using a general 
gradient at first. The column with the best retention, analyte recovery, and peak shape is 
selected for further optimization. Then the mobile phases, flow rates and gradients are 
optimized using the analyte in solvent and potential isobaric (same molecular weight) 
interferents in solvent to ensure chromatographic separation. 
2.1.4 Sample Preparation Optimization 
Optimization of the sample preparation process requires the use of actual patient 
matrix, such as serum or plasma. An attempt is made to remove any potential interferent 
that is not separated by the MS or LC method. In addition to separating interferences, the 
objective of the sample preparation is to further purify the sample from proteins, salts, 
phospholipids, and other agents that may potentially cause ion suppression (see next 
section), and to make sure the sample is compatible with LC-MS/MS analysis. 
There are several options available for purifying the sample, with the most 
commonly used three being: a) protein precipitation (PPT), b) liquid-liquid extraction 
(LLE) or c) solid phase extraction (SPE), which can be performed online or off-line 
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(Figure 2.3). There are automated systems available that perform these procedures and 
can be coupled to the LC-MS/MS system to speed up the process and provide higher 
through-put [13]. PPT is the quick and easy option, but it is very non-selective and can 
require frequent maintenance of the instrument because of the introduction of 
unnecessary matrix components onto the MS. On the other hand, LLE and SPE are 
technically laborious but offer much cleaner extracts. Additional sample pre-treatment 
that can be performed to optimize separation from interferences or enhance the sensitivity 
of the analyte is derivatization. Once the sample preparation procedure has been 
finalized, it is essential to re-optimize both the MS and the LC methods and to make sure 
all stages of the LC-MS/MS method are compatible and synchronized. 
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Figure 2.6: Graphical Depiction of Sample Preparation Methods. A. PPT is performed by 
adding a precipitating reagent (i.e. solvent, acid, and/or concentrated salt solution) to the 
biological matrix then mixing followed by centrifugation to precipitate the solids formed. 
I. Biological matrix; II. Biological matrix with precipitating reagent added; III. 
Precipitated solids with soluble compounds in the supernatant. B. LLE is performed by 
adding a water-immiscible solvent to the biological matrix then mixing and 
centrifugation followed by collection of the analyte layer. For LC, the next step involves 
evaporation of the solvent and reconstitution in mobile phase. I. Biological matrix; II. 
Biological matrix with water immiscible solvent added; III. All compounds mixed; IV. 
Separation of polar and non-polar compounds into water layer and water immiscible 
layer, respectively. C. SPE uses a solid support with specific chemistry to capture the 
analytes from the biological matrix then the support is washed followed by the elution of 
the analytes. I. Application of biological matrix and capture of the analytes; II. Washing 
of support to remove matrix and unwanted molecules; III. Application of eluting reagent; 
IV. Elution of the analytes. Reproduced from [14]. 
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2.2 LC-MS/MS Method Validation 
2.2.1 Matrix Effects 
Matrix effect is thought to occur mainly as a result of nonvolatile solutes 
originating from the sample matrix interfering with the ionization of the analyte-of-
interest.  Examples of materials shown to cause matrix effects include salts, ion-pairing 
agents, endogenous compounds, drugs, metabolites, and proteins. Importantly, the degree 
of matrix effects can be dependent on the concentration of analyte studied, which 
underscores the importance of using concentrations of analyte that reflect those that will 
be encountered under pathophysiological conditions. The post-column infusion method 
(Figure 2.8) presented here provides a qualitative assessment of matrix effects by 
identifying chromatographic regions where ion suppression/enhancement is most likely 
to occur. This test cannot be performed for endogenous compounds without an isotope-
labeled internal standard. Concentration of the analyte in the infusion solution should be 
equivalent to patient specimen concentrations in the reference range. 
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Figure 2.7: Post-Column Infusion Set-Up Used to Evaluate The Effect of Absolute Ion 
Suppression. The dashed line represents the signal of the analyte in solvent, while the full 
line is obtained when a blank patient matrix is injected. The arrow is pointing to a region 
of ion suppression. Reproduced from [15]. 
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2.2.2 Mixing Study 
The objectives of mixing study are two-fold: i) verify that the internal standard 
used accounts for matrix effects by behaving similarly to the analyte in the tested matrix 
and  ii) choose an alternative matrix to be used as calibration and/or dilution matrix. The 
mixing study should be performed for both exogenous and endogenous compounds. It is 
evaluated by extracting and injecting patient samples (n=6), a candidate matrix solution, 
and 1:1 mixtures of patient samples with the candidate matrix solution. The criteria for a 
passing test is the response ratio (analyte/IS) of each 1:1 mixture was within 20% of the 
theoretical response calculated from an average of the measured values of the patient and 
candidate matrix solution. 
2.2.3 Method Interference (based on CLSI EP7-A2 guideline) 
An interferent is a substance either exogenous or endogenous that affects or 
interferes with the measurement of a target analyte. An interferent study should be 
performed to assess the effects of common interferents on the target analytes. To 
determine if a substance would interfere under “worst case” conditions, the 
comprehensive interference screen should be conducted at the highest concentrations that 
a laboratory would expect to observe among patient specimens submitted for analysis.  
Since both positive and negative effects might occur from different mechanisms (e.g. 
hemoglobin has catalyst activity as well as strong absorbance in the visible spectrum) 
each substance should be tested at two different analyte concentrations to avoid the 
possibility that competing effects might cancel at the concentrations tested.  
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Alternatively, appropriate low and high controls or proficiency samples may be run 
containing multiple possible interfering substances.  A minimum of triplicate sample 
preparations/extractions using two different analyte concentrations is necessary.   
2.2.4 Analytical Measurement Range (AMR)/Linearity/Calibration 
The analytical measurement range determines the values over which an accurate 
and precise measurement may be obtained. Coefficient of variation (%CV)/relative 
standard deviation (%RSD) and recovery for each data point are used to determine the 
range with acceptable limits usually being defined as CV <20% and recovery between 80 
and 120%. The eventual calibration range is determined by the AMR. A 
calibration/standard curve defines the relationship between a given analyte concentration 
and instrument response. A calibration curve should include five to eight points covering 
the analytical measurement range if practically possible. After AMR is completed a full 
calibration should be performed with all assays.  The LOQ (Functional Sensitivity) is 
determined as the lowest concentration at which the CV is <20%, the recovery is within 
100±20%, and the peak has a signal to noise (S/N) ≥10.  
2.2.5 Method Carryover 
Limit of carryover is defined as the highest concentration tested that may NOT 
cause significant impact on subsequent analyses due to incomplete removal of the analyte 
from the analytical system. It is advisable to obtain a sample that is the highest possible 
concentration that could be encountered in the laboratory.  All samples greater than the 
approved carryover must have the next two (2) subsequent patient samples repeated. 
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Carryover is evaluated by 3 independent experiments each consisting of running two 
extractions in the sequence of low1-high-low2, where low2 is a re-injection of low1. A 
passing test means low1 is within 20% of low2, and that low2 is within 3 standard 
deviations of the low1 value. The standard deviation is determined using low1 values. 
High samples that are above assay linearity are diluted within the linear range and the 
values are back calculated. The dilution is used to determine actual concentration that 
action must be taken if value is higher.  
2.2.6 Assay Precision 
Precision determines the repeatability of the measured a target analyte. Both total 
and within-run (intra-assay) precision must be evaluated using three different analyte 
concentrations. The sequence used in the primary evaluation method is specifically 
designed also to allow the nearly uncorrelated estimation of the effects of non-linearity, 
sample carryover, proportional and constant bias, and linear drift. At this stage begin 
assaying quality control (QC) materials. Simple precision is also acceptable. The QC 
materials are made separately from precision samples but may be at the same analyte 
levels. A minimum of two QC levels need to be used. At least one QC sample is placed at 
the beginning and end of a batch and must be alternated.  
2.2.7 Method Comparisons 
Method comparison is a means of determining the assay accuracy. Comparisons that 
can be performed for this test are listed below in order of preference: 
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1. Reference Material: Assess accuracy by measuring certified reference materials if 
possible (e.g. NIST). If sanctioned by medical director no further testing required. 
2. Comparison with a Reference Method: Accuracy can also be estimated by 
measuring patient samples (~40 initially) by both the new method and a reference 
method.   
3. Commonly Used Method: If neither a reference material nor comparison with a 
reference method is available, a comparison may be done using a commonly used 
method (min 40 samples).     
2.3 Conclusion 
LC-MS/MS has become widely utilized in the clinical laboratory because it offers 
an unparalleled level of sensitivity and specificity for small molecule analysis. The 
process of developing and validating LC-MS/MS methods is rigorous and requires highly 
specialized training. However, the process is greatly facilitated by protocol and procedure 
standardization. With these in place the laboratory can be confident that they are 
producing accurate, precise, and reliable methods for clinical use.  
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CHAPTER III                                                                                     
PREDICTIVE VALUE OF STEROIDAL HORMONES TO 
TYPE 2 DIABETES AND METABOLIC SYNDROME 
3.1 Background 
Metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM) are costly 
diseases for the American people. MetS [1] and T2DM [2] are placing a major financial 
and health burden on the USA population with prevalence at about 23.7% and 8.3%, 
respectively. Consensus criterion for diagnosis of MetS was proposed by the International 
Diabetes Federation [3] (IDF; Table 3.1) but the etiology is still controversial. Those with 
MetS have a high occurrence of cardiovascular disease and T2DM. T2DM has been well 
documented in the USA and the American Diabetes Association (ADA) has issued 
diagnosis criteria [4] (Table 3.2) that are internationally implemented.  
Biomarkers for diagnosing these diseases are available.   However, accurate 
disease prediction has yet to be achieved using just these biomarkers and family history. 
We are attempting to improve a current risk score by adding specific steroid hormones to 
the calculation. The panel would include aldosterone, cortisol, and testosterone which 
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have been found outside established reference intervals for both MetS and T2DM and 
cortisone for which new research into the 11β-hydroxysteroid dehydrogenase type 1 and 
type 2 enzymes show correlations to obesity, a common companion to both MetS and 
T2DM. MetS and T2DM have shown strong correlations to the steroid hormones 
testosterone [5 6], aldosterone [7 8], and cortisol [9 10] and have been implicated in the 
disease progression.  
3.1.1 Metabolic syndrome 
MetS is a clustering of disorders that have been shown to increase the risk of 
developing cardiovascular disease and T2DM [11]. MetS has been known by various 
names most commonly ‘Syndrome X’ and ‘Insulin Resistance Syndrome’ which are 
related to the perspectives under which the conditions were characterized and are not 
strictly identical. There have been multiple attempts to define the syndrome but the 
attempts have suffered from an unknown etiology on which to center the diagnosis. The 
latest attempt at a consensus definition was proposed by the IDF and will be used for the 
research presented.   
The relationships between MetS and the steroids, aldosterone [7 8] and cortisol [9 
10], have been characterized. The Framingham Offspring Study (N=282) found 
aldosterone was a possible biomarker for MetS with an odds ratio of 1.21 (P=0.015) [7]. 
One study found cortisol (n=205) to be significantly elevated (10.4 vs. 8.9; P<0.01) in a 
pediatric Latino population [12].  Cortisol was shown to have an odds ratio of 3.443 
(P=0.024) for developing T2DM in people indicated as having subclinical Cushing’s 
syndrome which was defined by hypothalamus-pituitary-adrenal axis alteration without 
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classic symptoms. However, the relationship between MetS and cortisone has not been 
heavily characterized but there is recent data concerning 11 β-hydroxysteroid 
dehydrogenase type 1 enzyme [13 14] which performs an intercellular conversion of 
cortisone to cortisol that indicates a portion of the MetS related disorders are related to 
the function of this enzyme. 
3.1.2 Type 2 diabetes mellitus 
T2DM is defined by two factors: 1) An increased peripheral insulin resistance and 
2) a decreased insulin secretion from pancreatic islet cells. These two factors combine to 
give the symptoms seen in T2DM [4]. In addition the diagnosis of this disease is often 
missed until symptoms present which contributes to ~25% of people with T2DM going 
undiagnosed. 
Disruption to the production of testosterone [5 6], and cortisol [9 10] have been 
documented. One study found total testosterone (P<0.01) was independently associated 
with the log of the homeostatic insulin resistance (HOMA) model after correcting for 
covariants [5].  In another study, the cortisol levels of men aged 59-70 years born in 
Hertfordshire, England were significantly correlated with fasting plasma glucose 
(P=0.0002) and the 2 hour time point of an oral glucose tolerance test (P=0.04) [15].  
However, little work has been done concerning cortisone or a panel of these steroids in 
the populations of T2DM and metabolic normal patients. 
There are many steroid panels in the literature [16-26]. However, none seem to 
include aldosterone with the rest of the steroid panel. When testing for aldosterone a 
second method is used such as was done in Nakamura et al. [19]. In addition, steroid 
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panels appear to be purposed built for the conditions they are diagnosing. Here we 
propose to develop and validate a unique multi-analyte LC-MS/MS panel for steroid 
measurements with the purpose of establishing a risk score that will allow for the risk 
stratification for the development of MetS and T2DM. We will: 
Aim 1: Create a sensitive and accurate LC-MS/MS assay for a panel of 
steroids including aldosterone, testosterone, cortisol, and cortisone. Challenge: To 
measure multiple steroid hormones within one assay run at their low level of abundance 
while managing possible high background interference. Approach: Per stringent 
institutional and standardization guidelines, we will develop and validate an analytical 
methodology using a using a state of the art Prelude-Quantiva system which employs a 
microLC-MS/MS with the highest sensitivity mass spectrometer on the market.  
Aim 2: Perform a cross-sectional study to determine the diagnostic 
contribution of steroids, previously correlated to either MetS or T2DM, in high risk 
patients. Challenge: To retrieve or recruit adequate patient samples and develop an 
understanding of logistic regression calculations. Approach: We will collect leftover 
patient samples from the 2 hour oral glucose tolerance test and stratify primarily based on 
the diagnostic criteria for MetS and T2DM. We will compare the combined steroid panel 
score with a previously developed risk score for MetS and glucose level for T2DM. The 
previous risk score did not include any steroid or hormone information in the calculation 
which we will include to refine the risk score assessment. Impact: This study will attempt 
to extend an existing risk score calculation that has been provided by Dr. Hamaty. Either 
the steroid risk score or the combined risk score might allow the clinicians to improve 
treatment decisions.  
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Aim 3: Determine the contribution of cortisone as a biomarker for MetS and 
T2DM. Challenge: To determine if cortisone is a biomarker for MetS and/or T2DM. 
Approach: The 11β-hydroxysteroid dehydrogenase type 1 enzyme has been associated 
with obesity by previous studies and identified as a possible drug target. With the 
samples collected in Aim 2, we will determine if cortisone is an independent contributor 
to MetS and T2DM. Impact: This study will add knowledge concerning cortisone as a 
biomarker for MetS and T2DM which has not been systematically studied to date.  
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Table 3.1 MetS Definition from the IDF (modified from [3]) 
Central obesity (defined as waist circumference* with ethnicity specific values) plus any two of the 
following four factors: 
Raised TG level: 
≥ 150 mg/dL (1.7 mmol/L), or specific treatment for 
this lipid abnormality 
Reduced HDL 
cholesterol: 
< 40 mg/dL (1.03 mmol/L) in males and < 50 mg/dL 
(1.29 mmol/L) in females, or specific treatment for 
this lipid abnormality 
Raised blood pressure: 
systolic BP ≥ 130 or diastolic BP ≥ 85 mm Hg, or 
treatment of previously diagnosed hypertension 
Raised fasting plasma 
glucose (FPG): 
≥ 100 mg/dL (5.6 mmol/L), or previously diagnosed 
type 2 diabetes (If above 5.6 mmol/L or 100 mg/dL, 
OGTT is strongly recommended but is not necessary 
to define presence of the syndrome). 
* If BMI is >30kg/m², central obesity can be assumed and waist circumference does 
not need to be measured. 
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Table 3.2: Criteria for the Diagnosis of Diabetes (modified from [4]) 
A1C ≥6.5%. The test should be performed in a laboratory using a method that is NGSP certified and 
standardized to the DCCT assay.* 
OR 
FPG ≥126 mg/dL (7.0 mmol/L). Fasting is defined as no caloric intake for at least 8 h.* 
OR 
2-h PG ≥200 mg/dL (11.1 mmol/L) during an OGTT. The test should be performed as described by the WHO, 
using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water.* 
OR 
In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose ≥200 
mg/dL (11.1 mmol/L). 
 ↵* In the absence of unequivocal hyperglycemia, results should be confirmed by repeat testing. 
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3.2 Method development and validation 
3.2.1 Chemicals, reagents and solutions 
Methanol and acetonitrile (Burdick and Jackson High Purity Solvent) were from 
VWR (West Chester, PA, USA). Zinc sulfate monohydrate and ammonium formate were 
purchased from Sigma-Aldrich (>99.9% pure; St. Louis, Missouri, USA). Type 1 water 
was from a Millipore Synergy System (Billerica, MA, USA). Cortisol, testosterone, 
aldosterone, cortisone, d4-cortisol, and d3-testosterone (16, 16, 17-d3) were purchased 
from Cerilliant (Round Rock, Texas, USA). Charcoal stripped serum (CSS), SerumCon 
II, was purchased from SerumCare (Milford, MA, USA). A reverse phase column, 
Accucore C18 analytical column (3.0 x 50 mm, 2.6 micron) was purchased from Thermo 
Fisher Scientific (Waltham, MA, USA). 
Two different mixed sub-stocks were prepared in 1:1 methanol:water (v/v) for 
cortisol, testosterone, aldosterone, and cortisone (1 µg/mL). One sub-stock was used for 
preparation of standard calibration solutions, while the other was used for preparing 
quality controls and validation materials. The calibration standards were prepared by 
serial dilution in CSS at various concentrations (Table 3.3). IS stocks were prepared in 
1:1 methanol:water (v/v) at 500 ng/mL for d4-cortisol and d3-testosterone. All solutions 
were stored at -20°C in Pyrex 16 X 100 mm (Corning, NY, USA) culture tubes until use.   
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3.2.2 Sample Preparation 
Plasma (500 μL) collected using standard venipuncture in grey top vacutainer 
tubes (BD, Franklin Lakes, New Jersey, USA)  was vortex mixed with the IS solution (10 
µL; d4-cortisol and d3-testosterone 500 ng/mL in 1:1 methanol:water), followed by 
addition of 200 µL of 0.1 M zinc sulfate and 1 mL methyl-tert butyl ether.  The mixture 
was vortex mixed for 30 s and centrifuged at 2,000 g for 30 min. The organic layer (900 
µL) was transferred into a glass tube and dried under a flow of nitrogen at 35ºC. The 
residue was reconstituted with 1:1 methanol:water (v/v) (125 µL) and was transferred 
into a 1.5 mL microcentrifuge tube.  The microcentrifuge tube was centrifuged at 12,000 
g for 10 min. The supernatant was transferred into an injection vial and injected (50 μL) 
into the LC-MS/MS system for analysis.  
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Table 3.3. Calibration Levels for MetS/T2DM Steroid Panel 
  
Testosterone 
(pg/mL) 
Cortisol 
(ng/mL) 
Cortisone 
(ng/mL) 
Aldosterone 
(pg/mL) 
10000 350 50 1000 
5000 175.00 25.00 500 
2500 87.50 12.50 250 
625 21.88 3.13 62.50 
312.50 10.94 1.56 31.25 
156.25 5.47 0.78 
 
78.13 2.73 0.39 
 
 
0.68 0.10 
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3.2.3 LC-MS/MS method 
This method was developed on a Thermo Fisher Prelude LC system coupled to a 
TSQ Quantiva mass spectrometer. Instrument software for this study consisted of TSQ 
Quantiva Tune 1.0, Aria MX 2.1, and Tracefinder 3.2. The duplex LC system consisted 
of a robotic sampling arm and a refrigerated sampling compartment for six 96-well plates 
followed by independent inline degassers and LC syringe pumps.  The mobile phase 
consisted of 10 mM ammonium formate with 0.1% formic acid (A) and methanol (B). 
Samples were injected onto an Accucore C18 analytical column at a flow rate of 0.6 
mL/min as per Table 3.4. The total run time between injections for one channel is 4.25 
min (Figure . The mass spectrometer spray voltage was set to positive ionization at 2000 
V, the ion transfer tube temperature at 250°C, and the vaporizer temperature was set at 
450°C. The sheath gas was 38 U, the ion sweep gas was 0 U, and the aux gas was 20 U. 
The collision cell had a gas pressure of 1.5 U.  The collision energy and the selected 
reaction monitoring (SRM) transitions are in Table 3.5. The tube lens offset was set at 80 
V. Calibration was based on peak area ratios of analyte to the IS over the concentrations 
with 1/x
2
 fitting.  
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Figure 3.1: Steroid Panel Chromatogram. 
Typical chromatogram of charcoal stripped serum spiked with 500 pg/mL of aldosterone 
and testosterone and 5 ng/mL of cortisone and cortisol. 
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Table 3.4: MetS/T2DM Steroid Panel Chromatography Conditions 
Time 
(min) 
Gradient 
type 
Mobile Phase 
Ratio 
A B 
0 step 75 25 
0.75 ramp 50 50 
1.25 ramp 30 70 
2.25 ramp 10 90 
3.25 step 5 95 
3.5 step 0 100 
3.75 step 75 25 
Mobile phase A = 10 mM ammonium formate with 0.1% (v/v) formic acid 
Mobile phase B= methanol 
 
 
 69 
Table 3.5:  MetS/T2DM Steroid Panel SRM Transitions and Collision Energy 
 
Analyte 
Precursor 
ion (m/z) 
Product 
ions 
(m/z) 
Collision 
energy 
(eV) 
testosterone 289.2 97.2 24 
    109.2 27 
d3-testosterone 292.2 97.2 24 
cortisol 363.3 121.1 26 
  
 
267.1 19 
d4-cortisol 367.4 121.1 26 
cortisone 361.3 121.1 19 
    161.1 21 
aldosterone 361.3 315.4 20 
    343.3 17 
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3.2.4 Method validation procedure 
Initial ion suppression evaluation was performed by post-column infusion of a 
saline solution containing 500 ng/mL of d4-cortisol and d3-testosterone, while extracted 
patient samples (3 males and 3 females) without IS were injected into the system. 
Relative ion suppression was studied to test whether the IS accounted for ion suppression 
for the analytes in the matrix. It is evaluated by extracting and injecting a CSS spiked 
sample with aldosterone, cortisone, cortisol, and testosterone at 0.83, 33, 33, and 0.83 
ng/mL, respectively, 6 patient samples (3 males and 3 females), and 1:1 mixtures of 
patient samples with the saline solution. The criteria for passing is the response ratio 
(analyte/IS) of each 1:1 mixture was within 20% of the theoretical response calculated 
from averaging the measured values for the patient and saline solution. Analytical 
measurement range (AMR) was examined in triplicate by serially diluting spiked pooled 
serum with CSS. From these samples, the AMR was determined based on three factors: 
accuracy within 100 ± 20%, a coefficient of variation (CV) within 20%, and a signal to 
noise greater than 10. Carryover was performed in triplicate and consisted of running a 
high spiked sample and a low unspiked sample with a concentration below a typical late-
night specimen in the sequence of low1-high-low2, where low2 is a re-injection of low1. 
Carryover is considered acceptable if low2 is within 20% of low1 and low2 is within 3 
standard deviations of the low1 value. The standard deviation was determined using only 
low1 values. Precision was evaluated using a simple precision with intra-assay (n=8) and 
inter-assay (n=15) with 3 samples a day for 5 days. Quantitative comparison (n=5) was 
performed with another LC-MS/MS method offered. 
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3.2.5 Sample Collection 
Leftover patient samples (~1 mL) were collected from each time point during the 
2 hour oral glucose tolerance test of fasting plasma glucose performed on main campus at 
CC laboratories. These tests are indicated for patients at high risk for T2DM and MetS. 
Ideally, 200 patient samples from each group corresponding to normal, defined by no 
metabolic abnormality, and MetS and T2DM with a 1/3 male to 2/3 female distribution 
will be collected. Comorbidities such as chronic kidney disease and cardiovascular 
disease will be noted as will HbA1c, VLDL, triglycerides, and ALT. Exclusion criteria 
will include long-term steroid use, bariatric surgery, pregnancy, Cushing’s syndrome, and 
liver disease. Subsequent to collection the sample will be frozen at -70°C until analytical 
analysis. Statistical analysis will involve ROC curve analysis, box-and-whisker plots, and 
multivariate regression analysis. A previous study to determine a risk score for T2DM 
was proposed by Dr. Hamaty and focused on gender, race, smoking, family history of 
diabetes, age, BMI, systolic and diastolic blood pressure, HbA1c, LDL, HDL, VLDL, 
triglycerides, and the liver enzyme ALT. The strongest factors were age, BMI, VLDL, 
triglycerides, and ALT. The concordance index for these was 0.755, an increase over 
random chance (0.50). This indicates there is still room for improvement of the model. 
Significance testing (t-test) will be used to determine statistical differences (p-value 
<0.01) between the groups.  
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3.2.6 Results 
3.2.7 Method validation 
No significant ion suppression was observed. The mean difference for the mixing 
study samples (n=6) was 8.9%, 2.0%, -0.4%, and 0.11% for aldosterone, cortisone, 
cortisol, and testosterone, respectively. The AMR was determined to be 30-1000 pg/mL 
for aldosterone, 1-80 ng/mL for cortisone, 2-500 ng/mL for cortisol, and 50-10000 pg/mL 
for testosterone (see Tables III.6-9). No significant carryover was observed up to ULOQ 
of the assays. The intra-assay CV was ≤8.5% for all analytes (Table 3.10), while the 
inter-assay CV ranged from 3.8-32.1%. Comparisons (n=5) with an independent 
commercial LC-MS/MS method were found to be acceptable for cortisol, cortisone, and 
testosterone. Due to the excessively high imprecision values for aldosterone, it was found 
to be unacceptable for routine clinical testing and will not be used for further analysis 
(Table 3.10). This might be resolvable with a genuine isotope-replaced internal standard 
which is currently not commercially available.  
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Table 3.6: Aldosterone AMR Data 
Analyte Spiked Expected Mean %CV 
Analytical 
Recovery 
Aldosterone pg/mL pg/mL pg/mL 
 
  
     
  
Blank 0.0 NA 75.0 6.72 NA 
Level 1 7.8 8.4 9.4 38.15 113.3 
Level 2 15.6 16.8 6.4 12.78 33.7 
Level 3 31.3 33.6 30.4 5.16 89.8 
Level 4 62.5 67.2 65.8 5.17 97.7 
Level 5 250.0 268.8 230.4 11.72 84.7 
Level 6 500.0 537.5 456.5 3.60 83.8 
Level 7 1000.0 1075.0 926.7 1.66 85.2 
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Table 3.7: Cortisone AMR Data 
Analyte Spiked Expected Mean %CV 
Analytical 
Recovery 
Cortisone ng/mL ng/mL ng/mL 
  
      
Blank 0.0 NA 22.8 0.63 NA 
Level 1 0.1 0.1 0.3 9.74 248.1 
Level 2 0.2 0.3 0.5 12.38 193.4 
Level 3 0.4 0.6 0.8 1.28 151.7 
Level 4 0.8 1.1 1.3 3.49 119.8 
Level 5 1.6 2.3 2.4 3.66 106.3 
Level 6 3.1 4.6 4.7 1.03 104.8 
Level 7 12.5 18.2 19.6 3.40 111.1 
Level 8 25.0 36.4 39.9 1.78 113.9 
Level 9 50.0 72.8 83.6 1.46 121.5 
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Table 3.8: Cortisol AMR Data 
Analyte Spiked Expected Mean %CV 
Analytical 
Recovery 
Cortisol ng/mL ng/mL ng/mL 
  
      
Blank 0.0 NA 164.0 2.25 NA 
Level 2 0.7 1.0 1.0 54.13 99.4 
Level 3 1.4 2.0 2.2 5.47 114.9 
Level 4 2.7 4.0 4.4 0.37 112.6 
Level 5 5.5 8.0 8.2 1.77 103.6 
Level 6 10.9 16.1 16.3 1.20 102.3 
Level 7 21.9 32.1 33.7 2.00 107.2 
Level 8 87.5 128.5 131.1 2.40 103.0 
Level 9 175.0 257.0 252.8 2.55 97.6 
Level 10 350.0 514.0 499.8 1.64 96.0 
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Table 3.9: Testosterone AMR Data 
Analyte Spiked Expected Mean %CV 
Analytical 
Recovery 
Testosterone pg/mL pg/mL pg/mL 
  
      
Blank 0.0 NA 298.0 2.89 NA 
Level 1 19.5 20.1 46.8 20.32 236.90 
Level 2 39.1 40.2 47.7 8.86 119.20 
Level 3 78.1 80.5 87.6 8.03 109.12 
Level 4 156.3 160.9 155.7 3.97 96.66 
Level 5 312.5 321.8 316.9 2.11 98.44 
Level 6 625.0 643.6 657.4 1.16 102.21 
Level 7 2500.0 2574.5 2628.2 2.38 102.15 
Level 8 5000.0 5149.0 5048.8 1.05 98.00 
Level 9 10000.0 10298.0 10225.8 1.60 99.28 
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Table 3.10: MetS/T2DM Steroid Panel Precision 
Analytes 
  
Aldosterone 
(pg/mL) 
Cortisone 
(ng/mL) 
Cortisol 
(ng/mL) 
Testosterone 
(pg/mL) 
Intra-assay Mean 
Low 221 46 239 812 
Mid 313 71 326 2610 
High 392 88 369 4168 
Intra-assay %CV 
Low 7.1 3.5 4.8 3.6 
Mid 3.4 2.9 3.2 2.8 
High 8.5 5.2 4.6 6.5 
Inter-assay Mean 
Low 268 48 241 797 
Mid 388 72 316 2607 
High 478 92 383 4277 
Inter-assay %CV 
Low 22.6 9.0 5.8 5.8 
Mid 32.1 12.2 6.4 4.9 
High 23.6 7.9 3.8 6.1 
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3.2.8 Sample statistics 
Samples were collected, processed, and were found to have the characteristics in 
Table 3.11. Smoking status and lipid panels were not included in the data collection due 
to insufficient data for modeling. Fasting samples were used for all calculations. Box-
and-whisker plots were performed for male testosterone, cortisol, and cortisone (Figures 
III.1-4). The box-and-whisker plot would indicate there is significant overlap of the data 
in the three populations. Despite the information from the box-and-whisker plots, ROC 
curve analysis was performed on the individual analytes in relation to MetS and T2DM 
(Figure 3.5-6). Based on the ROC curve analysis, the individual steroid hormones 
measured have little influence on the diagnosis of either MetS or T2DM. Logit regression 
was performed for the binary case of MetS vs. normal metabolism (Table 3.12 and Figure 
3.7) and T2DM vs. normal metabolism (Table 3.13 and Figure 3.8) using the RealStats 
add-in for Excel. Any analyte that was followed with –avg was missing data and the 
average of the data was substituted for the missing information. To keep track of the 
effect of the average value a dummy variable was established with the –avg indication. If 
the –avg was significant in the model then the missing variable replacement had an effect 
and should not be used in the final model. For the MetS logit regression model, it was 
found that with the information monitored at a p-value of <0.05 intercept, potassium-avg, 
HbA1c, and OGTT-1hr were significant contributors to the model and at a p-value of 
<0.1 testosterone, ALT-avg, cortisone, and cortisol were found to be significant 
contributors. When the variables with p-values >0.1 were excluded the steroid hormone 
p-values were >0.1. All the steroid hormones were insignificant contributors of the MetS 
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logit regression model with the current information. For the T2DM model, at a p-value 
<0.01 collection time and HbA1c, at p-value of <0.05 cortisone, and at p-value <0.1 
height were significant to the model. When the variables with p-values >0.1 were 
excluded cortisone’s p-value was 0.048.  Out of the steroid hormones only cortisone 
showed any contribution to the model. 
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Table 3.11: Patient Specimen Characteristics 
Characteristics  Female Male 
Total, N 96 67 
MetS, n(%) 18(19) 18(27) 
T2DM, n(%) 13(14) 7(10) 
Normal, n(%) 71(74) 48(72) 
 
  
Collection Time, mean(std) 1065(226) 1062(252) 
Age, mean(std) 46(16) 55(16) 
Height, mean(std) 165(8) 173(11) 
Weight, mean(std) 83(22) 88(19) 
BMI, mean(std) 30(8) 29(5) 
Glucose 0hr, mean(std), mg/dL 91(13) 92(14) 
Glucose 1hr, mean(std), mg/dL 163(57) 159(58) 
Glucose 2hr, mean(std), mg/dL 128(58) 117(50) 
 
  
Testosterone 0hr, mean(std), pg/mL 519(1145) 2691(2379) 
Testosterone 1hr, mean(std), pg/mL 454(1001) 2180(1895) 
Testosterone 2hr, mean(std), pg/mL 451(1048) 2290(1946) 
Cortisol 0hr, mean(std), ng/mL 112(64) 115(45) 
Cortisol 1hr, mean(std), ng/mL 89(47) 98(40) 
Cortisol 2hr, mean(std), ng/mL 75(40) 85(38) 
Cortisone 0hr, mean(std), ng/mL 26(12) 28(13) 
Cortisone 1hr, mean(std), ng/mL 21(11) 25(12) 
Cortisone 2hr, mean(std), ng/mL 21(11) 23(10) 
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Figure 3.2: Box-and-Whisker Plot of Male Testosterone Values. 
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Figure 3.3: Box-and-Whisker Plot of Female Testosterone Values. 
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Figure 3.4: Box-and-Whisker Plot of Combined Male and Female Cortisol Values. 
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Figure 3.5: Box-and-Whisker Plot of Combined Male and Female Cortisone Values. 
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Figure 3.6: ROC Curve for MetS and Various Individual Analytes. 
Area under the curve (AUC) greater than 0.5 indicates a relationship between the analyte 
and the diagnosis of MetS. Considering the 95% confidence intervals (CI) the individual 
steroid hormones have little to no effect on the diagnosis of MetS. 
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Figure 3.7: ROC Curve for T2DM and Various Individual Analytes. 
Area under the curve (AUC) greater than 0.5 indicates a relationship between the analyte 
and the diagnosis of T2DM. Considering the 95% confidence intervals (CI) the individual 
steroid hormones have little to no effect on the diagnosis of T2DM. 
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Table 3.12: Logit Regression Coefficients and p-values for MetS 
  coeff b p-value 
Intercept -26.7403 0.001068 
Potassium-Avg -2.07684 0.010739 
HbA1c 2.732075 0.023186 
OGTT-1hr 0.015194 0.033932 
Testosterone -0.00033 0.074498 
ALT-Avg 1.197075 0.080614 
Cortisone 0.042905 0.085802 
Cortisol -0.00947 0.096236 
Gender 0.905527 0.154583 
Age 0.016109 0.333788 
Collection Time 0.001303 0.371624 
Potassium 0.534636 0.423249 
OGTT-Ohr 0.018671 0.430687 
OGTT-2hr -0.00399 0.558631 
ALT 0.015365 0.615525 
HbA1C-Avg -0.05599 0.918903 
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Figure 3.8: ROC Curve for MetS using the Logit Regression of Values in Table 3.12. 
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Table 3.13: Logit Regression Coefficients and p-values for T2DM 
  coeff b p-value 
HbA1c 4.438326 0.001741 
Collection Time 0.005639 0.003312 
Cortisone 0.087813 0.036549 
Height -0.46791 0.054114 
Weight 0.385441 0.10278 
BMI -1.00732 0.114108 
Age 0.040297 0.141406 
HbA1c-Avg -0.95246 0.280066 
Intercept 36.31161 0.338765 
Potassium-Avg -1.05486 0.520262 
Gender -0.65687 0.558673 
ALT -0.01691 0.62897 
Potassium 0.607524 0.629393 
ALT-Avg -0.26374 0.86139 
Testosterone 5.99E-05 0.866547 
Cortisol 0.001062 0.912879 
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Figure 3.9: ROC Curve for T2DM using the Logit Regression of Values in Table 3.13. 
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3.3 Conclusion 
Specific information used in Dr. Hamaty’s model was not able to be collected for 
this study due to limited data in the charts and there was not sufficient sample volume to 
perform the test. As such, these pieces of information were not included in the model and 
a direct comparison to Dr. Hamaty’s model was not possible. The final model for MetS 
only had HbA1c and OGTT-1hr as significant contributors. These variables are not novel 
since they are established biomarkers for diabetes. However, there were some interesting 
variables for the T2DM model. Collection time was not expected to have an impact on 
T2DM but may have had impact on cortisol or testosterone due to diurnal variation. Two 
hypotheses surfaced when collection time was explored. Hypothesis one is collection 
time is important due the scheduling of a specific patient population. The second and 
more likely is collection time is important due to fasting. The initial sample for the oral 
glucose tolerance test (OGTT) is indicated to be fasted. However, if a patient is scheduled 
later in the day for the OGTT they are less likely to have fasted the required time. This 
may increase the baseline glucose in the system increasing the likelihood of the OGTT-
2hr to be >200mg/dL which is the defined cut-off for diabetes. More work will be 
required to determine if either of these hypotheses are correct or if there is another 
explanation.  
Cortisone (p-value <0.05) was the only steroid in this study to show any direct 
relationship to T2DM while no steroid had a demonstrated relationship to MetS. 
However, there are two major issues with the current study. First it is a cross-sectional 
study and second the final count of T2DM was only 20 individuals. Due to the issues 
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with this study, cortisone may be important but needs further studies to assess this 
finding. These issues could be addressed through a prospective study that can directly 
collect samples from metabolic normal and T2DM individuals.  
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CHAPTER IV                                                                  
VERIFICATION OF MORNING AND LATE NIGHT 
SALIVARY CORTISOL REFERENCE INTERVALS FROM A 
REFERENCE POPULATION USING A QUANTITATIVE 
LC-MS/MS METHOD 
 
4.1 Background 
Cortisol is a steroid enzymatically derived from cholesterol in the adrenal gland 
that undergoes a cyclic diurnal variation in circulation with the lowest concentrations late 
at night and the highest in the morning [1 2].  In patients with Cushing’s syndrome the 
diurnal variation is lost. Salivary cortisol levels correlate well with free cortisol levels in 
blood, and may be the preferred specimen due to the sample collection convenience. 
Late-night salivary cortisol has been found to be useful for multiple purposes such as a 
valuable marker for post procedure remission of Cushing’s disease [3] and  
responsiveness to drugs [4]. However, late-night salivary cortisol is most important for 
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diagnosis of Cushing’s syndrome [2], and is currently recommended by the Endocrine 
Society [5]. 
The salivary cortisol cutoff by liquid chromatography-tandem mass spectrometry 
(LC-MS/MS) in the literature varies from 3.0–21.0 nmol/L for morning [6] and 2.7 to 3.0 
nmol/L for late night [7].   LC-MS/MS methods are generally preferred due to the high 
specificity and sensitivity [8]. The objective of this work was to establish a sensitive LC-
MS/MS method for measuring salivary cortisol and to verify the reference intervals for 
morning and late-night levels in a local reference population. 
4.2 Material and methods 
4.2.1 Chemicals, reagents and solutions 
Methanol and acetonitrile (Burdick and Jackson High Purity Solvent) were from 
VWR (West Chester, PA, USA). Type 1 water was from a Millipore Synergy System 
(Billerica, MA, USA). Cortisol was purchased from two separate suppliers Cerilliant 
(2.76 mmol/L [1 mg/mL], 98.6% purity; Round Rock, Texas, USA) and Sigma-Aldrich 
(St. Louis, MO, USA). The Sigma-Aldrich powder was dissolved in methanol into a 2.76 
mmol/L (1 mg/mL) stock solution. The internal standard (IS), d4-cortisol was purchased 
from Cerilliant (272 µmol/L [100 µg/mL], 99.2% purity). Saline (as 0.9% sodium 
chloride irrigation, USP) was obtained from Baxter Healthcare Corporation (Deerfield, 
IL, USA). A reverse phase column, Accucore C18 analytical column (3.0 x 50 mm, 2.6 
micron) was purchased from Thermo Fisher Scientific (Waltham, MA, USA). 
Two different sub-stocks were prepared in 1:1 methanol:water (v/v) for cortisol 
(2.76 µmol/L [1 µg/mL]). One sub-stock was used for preparation of standard calibration 
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solutions, while the other was for preparing quality controls and validation materials. The 
calibration standards were prepared by serial dilution in saline at 41.1, 20.7, 10.4, 5.2, 
2.6, and 1.3 nmol/L [15.0, 7.5, 3.8, 1.9, 0.9 and 0.5 ng/mL] for cortisol. IS stocks were 
prepared in  at 13.6 nmol/L [5 ng/mL] for d4-cortisol. All solutions were stored at -20°C 
in Pyrex 16 X 100 mm (Corning, NY, USA) culture tubes until use.   
4.2.2 Sample Preparation 
 Saliva (200 μL) collected using a Salivette device (Sarstedt, Newton, NC, USA) 
was vortex mixed with the IS solution (50 µL; d4-cortisol 13.6 nmol/L in 1:1 
methanol:water), followed by addition of 1 mL of methyl-tert butyl ether.  The mixture 
stood at room temperature for an hour then was vortex mixed for 30 s, and centrifuged at 
2,000 g for 3 min. The organic layer (900 µL) was transferred into a glass tube and dried 
under a flow of nitrogen at 35ºC. The residue was reconstituted with 1:1 methanol:water 
(v/v) (200 µL) and injected (25 μL) in the LC-MS/MS system for analysis.  
4.2.3 LC-MS/MS method 
This method was developed on a Thermo Fisher Prelude LC system coupled to a 
TSQ Quantiva mass spectrometer. Instrument software for this study consisted of TSQ 
Quantiva Tune 1.0, Aria MX 2.1, and Tracefinder 3.2. The duplex LC system consisted 
of a robotic sampling arm and a refrigerated sampling compartment for six 96-well plates 
followed by independent inline degassers and LC syringe pumps.  The mobile phase 
consisted of water (A) and methanol (B). Samples were injected onto an Accucore C18 
analytical column at a flow rate of 0.6 mL/min as per Table 4.1. The total run time 
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between injections for one channel is 4.25 min. The mass spectrometer spray voltage was 
set to positive ionization at 2000 V and the ion transfer tube temperature at 280°C. The 
sheath gas was 35 U, the ion sweep gas was 0 U, and the aux gas was 18 U. The collision 
cell had a gas pressure of 2.5 U.  The collision energy was 26V for the 363.3 m/z->121.2 
m/z and 367.4 m/z ->121.1 m/z transitions and 19V for the 363.3 m/z ->267.1 m/z and 
367.4 m/z ->273.1 m/z transitions. The tube lens offset was set at 80 V. Selected reaction 
monitoring was set to monitor the transitions 363.3 m/z ->121.2 m/z and 363.3 m/z -
>267.1 m/z for cortisol and 367.4 m/z ->121.1 m/z and 367.4 m/z ->273.1 m/z for d4-
cortisol.  Calibration was based on peak area ratios of cortisol to the IS over the cortisol 
concentrations with 1/x
2
 fitting.  
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Table 4.1: Salivary Cortisol Chromatography Conditions 
Time 
(min) 
Gradient 
type 
Mobile Phase 
Ratio 
A B 
0 step 75 25 
0.75 ramp 50 50 
1.25 ramp 30 70 
2.25 ramp 10 90 
3.25 step 5 95 
3.5 step 0 100 
3.75 step 75 25 
Mobile phase A = water 
Mobile phase B= methanol 
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4.2.4 Method validation 
Initial ion suppression evaluation was performed by post-column infusion of a 
saline solution containing 1366 nmol/L of d4-cortisol, while extracted patient samples (3 
males and 3 females) without IS were injected into the system. Relative ion suppression 
was studied to test whether the IS accounted for ion suppression for the analytes in the 
matrix. It is evaluated by extracting and injecting a saline spiked with cortisol at 55.2 
nmol/L, 6 patient samples (3 males and 3 females), and 1:1 mixtures of patient samples 
with the saline solution. The criteria for passing is the response ratio (analyte/IS) of each 
1:1 mixture was within 20% of the theoretical response calculated from averaging the 
measured values for the patient and saline solution. Analytical measurement range 
(AMR) was examined in triplicate by serially diluting cortisol spiked pooled saliva with 
saline. From these samples, the AMR was determined based on three factors: accuracy 
within 100 ± 20%, a coefficient of variation (CV) within 20%, and a signal to noise 
greater than 10. Carryover was performed in triplicate and consisted of running a high 
spiked sample and a low unspiked sample with a concentration below a typical late-night 
specimen in the sequence of low1-high-low2, where low2 is a re-injection of low1. 
Carryover is considered acceptable if low2 is within 20% of low1 and low2 is within 3 
standard deviations of the low1 value. The standard deviation was determined using only 
low1 values. Precision was evaluated using a modified protocol based on the Clinical 
Laboratory and Standards Institute (CLSI) EP10-A3 guideline (Wayne, PA, USA) 
and included running the sequence mid-hi-low-mid-mid-low-low-hi-hi-mid twice a day 
for 5 days using patient derived samples to determine both intra-assay and total CVs.  
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Quantitative comparison (n=33) was performed with another LC-MS/MS method offered 
by Lurie Children's Hospital clinical laboratory (Chicago, IL, USA). 
4.2.5 Sample collection for reference range study 
Recruitment of the reference subjects in this study was approved by the 
Institutional Review Board. In brief, saliva was collected in a Salivette Code Blue 
Cortisol device (CAT# 51.1534.500, Sarstedt, Newton, NC, USA) from 41 healthy adults 
(22 females), aged 19-71 y (45 ± 14). The exclusion criteria were: working night shift, 
taking any systemic steroid medications, or using any topical steroid cream. Morning 
samples were collected between 06:00-08:00 and late-night samples were collected 
between 23:00-0:00. Saliva collection instructions were: no brushing/flossing teeth prior 
to collection; no drinking coffee, alcohol or juice 4 hours before collection; no 
eating/drinking anything 30 min prior to collection; refrain from smoking; no applying 
creams or lotions immediately prior to collection; rinse mouth with water 10 minutes 
before collection; remove the top cap from the container and place the swab directly into 
the mouth; no chewing/touching the swab. The saliva soaked Salivettes were shipped, 
centrifuged, and frozen (-70ºC) until analysis. Statistics were calculated using Excel 
(Microsoft, Redmond, WA, USA) or EP Evaluator Release 10 (Data Innovations, South 
Burlington, VT, USA).  
  
 103 
4.3 Results and Discussion 
4.3.1 Chromatography 
Total analytical cycle time, including column re-equilibration, was 4.25 min using 
a single LC channel. Two chromatographic peaks in cortisol transitions were resolved 
(Figure 4.1). A peak was seen at 0.65 min before the cortisol peak only in patient 
samples. At first we thought that the peak might be a contaminant in the Salivette 
devices. An experiment was performed to put the saline through the Salivette. Saline 
processed in this manner did not have the mystery peak. This made us believe it was 
endogenous. Based on the extraction method being used, the compound should be 
hydrophobic and most likely a steroid or phospholipid. We queried PubChem database 
with the molecular weight and performed a full scan of the peak to determine the specific 
fragments. PubChem database search returned many possibilities which we narrowed 
down based on the type of compounds and knowledge of the endogenous steroid 
synthesis and degradation pathways. This left a few possibilities but 18-
hydroxycorticosterone seemed most likely. We then procured a pure 18-
hydroxycorticosterone standard and confirmed the fragments and retention time. 
Therefore, the peak at 0.65 min was identified as 18-hydroxycorticosterone, which is 
known to be in saliva [9 10]; however, to the best of our knowledge, 18-
hydroxycorticosterone has not been observed in saliva while monitoring for cortisol by 
LC-MS(/MS). This is interesting because the two compounds share the same MW and the 
same product ions. It could be the second peak seen in the Owen et al. and McWhinney et 
al. reports [11 12].   
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4.3.2 Assay validation 
No significant ion suppression was observed. The mean difference for the mixing 
study samples (n=6) was -2.44%. AMR was determined to be 0.8 to 43.1 nmol/L with the 
accuracy ranging from 95 to 118% (Table 4.2). No significant carryover was observed up 
to 131 nmol/L. The total CV was 14.8%, 7.3%, and 6.6% at 1.9, 29.5, and 59.6 nmol/L, 
respectively. Comparison (n=33) with an independent LC-MS/MS method offered by 
Lurie Children's Hospital clinical laboratory gave a Deming regression correlation 
coefficient (R) of 0.925, slope of 1.04, an intercept of -0.006, and a standard error of 
estimate of 0.86. The mean bias between these two methods was 3.6%.  
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Figure 4.1:  A Representative Chromatogram.  Selected reaction monitoring for the 
quantitative transitions of extracted patient saliva sample (0.8nmol/L): cortisol (363.3 m/z 
->121.2 m/z) and d4-cortisol (367.4 m/z ->121.1 m/z). 
 
  
 106 
Table 4.2: Precision and Recovery Data from the AMR Study 
 
Mean, 
nmol/L 
%CV 
Analytical 
recovery 
 0.6 1.7 160 
 0.8 3.9 118 
 1.4 7.7 106 
 2.8 3.2 99 
 9.9 4.9 95 
 20.4 2.4 97 
 43.0 3.6 102 
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Though the number of subjects included in our study was small, they covered a 
wide age range with well-defined criteria using a thoroughly validated LC-MS/MS 
method. Samples were collected as paired sets (n=41); however, some of the samples 
collected at the early stage of the study did not have sufficient volume to perform the test. 
This prompted a change in the sample collection instructions directing the subject to wait 
until the swab was completely saturated. The morning cortisol results displayed a slightly 
positive skew in the distribution for this reference population (Figure 4.2). The reference 
interval for the morning salivary cortisol (n=35) using a log transformed parametric 
method provided an overall range of 2.8 to 27.6 nmol/L, while the late-night range 
(n=41) was <2.8 nmol/L by nonparametric method (central 95%). Both the morning and 
late-night ranges compared well with previous studies by LC-MS/MS methods which 
were 3.0-21.0 nmol/L for morning [6] and up to 2.7-3.0 nmol/L for late-night [7], 
respectively. 
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Figure 4.2: Reference Range Study. 
(A) Histogram of samples used to determine the reference range for the morning salivary 
cortisol from a Cleveland, Ohio population. Scattered plotting revealed a slightly skewed 
distribution of the reference population (n = 35). Using a log transformed parametric 
method for calculating the reference interval for cortisol provides a range 2.8 to 27.6 
nmol/L. (B) Probability plot of the original data and the log transformed data indicating 
an improved Gaussian distribution with the transformation.  
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4.4 Conclusion 
The validation of salivary cortisol indicated the assay was appropriate for clinical 
use. Additionally, the reference intervals from a local reference population using this LC-
MS/MS method have been confirmed to be 2.8-27.6 nmol/L and <2.8 nmol/L for 
morning and late-night collections, respectively. Currently, clinical studies are being 
performed using this assay to determine cyclical Cushing’s syndrome patterns and as 
follow-up to patients receiving cortisol injections. 
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CHAPTER V                                                                             
LC-MS/MS METHOD FOR CONGENITAL ADRENAL 
HYPERPLASIA 
5.1 Background 
Steroids, non-polar small molecule hormones, are enzymatically derived from 
cholesterol and regulate metabolic processes through the endocrine system [1]. These 
hormones are essential to proper physical development, sexual differentiation and 
maturation, and metabolic homeostasis. Steroids are produced mainly in the adrenal 
glands, placenta, and gonads and are separated into classes (progestogens, 
glucocorticoids, mineralocorticoids, androgens and estrogens) based on their metabolic 
function.  
Steroid testing is helpful for determining various disorders of the endocrine 
system such as congenital adrenal hyperplasia (CAH), aldosteronism, and Cushing’s 
syndrome. CAH can be broken down into three clinical forms with five distinct enzyme 
deficiencies. The most severe form is  the salt wasting (SW-CAH) followed by the simple 
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virilizing (SV-CAH) followed by the late onset non-classical (NC-CAH) form [2]. State 
mandated screening of CAH is targeted for detection of the SW-CAH using 17-
hydroxyprogesterone, which allows for the identification of 21-hydroxylase deficiency 
(21-OHD) that accounts for 90-95% of CAH cases [1]. However, this screening may miss 
the other four genetic variants which account for the remaining 5-10% of CAH or the 
SV-CAH and NC-CAH forms. Initially, CAH patients are tested to establish the CAH 
diagnosis then later to monitor treatment. Other steroids that are important for detecting 
the remaining CAH genetic variants and less severe forms include aldosterone, cortisol, 
cortisone, androstenedione, progesterone, pregnenolone, 11-deoxycortisol, and 21-
deoxycortisol. Aldosterone testing is applicable for the detection of SW-CAH as well as 
Conn’s syndrome (adrenal adenoma) and other primary hyperaldosteronism [3]. Cortisol 
testing helps the clinician to separate related disorders include Cushing’s syndrome, 
Addison’s disease, and others [4]. In addition, testosterone, androstenedione, and DHEA 
can be utilized to test for the presence of hyperandrogenism [1]. All of the noted 
disorders require steroid determination in order to properly diagnose and treat the 
patients. Proper steroid interpretation is reliant on the establishment of assay specific 
reference intervals. 
The standard testing methodology for CAH consists of screening for 17-
hydroxyprogesterone and many LC-MS methods target only 17-hydroxyprogesterone [5-
12], while others measure multiple steroids to improve diagnostic sensitivity [13-21]. For 
the detection of the most common CAH variant, 21-hydrxoylase deficiency, 17-
hydroxyprogesterone is required and diagnostic sensitivity can be augmented by 
measuring androstenedione, cortisol, and 21-deoxycortisol [22]. 21-deoxycortisol also 
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adds diagnostic sensitivity for detecting 21-hydrxoylase deficiency [23]. In order to 
detect 11-hydroxlyase deficiency, 11-deoxycortisol should be measured. Additionally, 
androstenedione and cortisol can be added to improve sensitivity [22]. The enzymatic 
deficiencies of 3β-hydroxysteroid dehydrogenase and 17α-hydroxylase, which are rarer, 
require the measurement of either [progesterone, pregnenolone/17-hydroxypregnenolone, 
and 17-hydroxyprogesterone] or [progesterone, 17-hydroxyprogesterone, 
androstenedione, and dehydroepiandrosterone] based on the enzymatic blockages 
involved. Lipoid CAH, the rarest form of CAH, is a result of the inability to convert 
cholesterol into pregnenolone so the ideal test target would be pregnenolone. With the 
goal of creating a screening steroid panel for all the possible CAH enzyme deficiencies, 
one would measure 17-hydroxyprogesterone, progesterone, pregnenolone, cortisol, 
androstenedione, 11-deoxycortisol, 21-deoxycortisol, and aldosterone. However, no 
single assay currently measures all of these. To detect both 21-hydrxoylase deficiency 
and 11-hydroxlyase deficiency, which accounts for >95% of the CAH variants, one 
would have to measure 17-hydroxyprogesterone, cortisol, androstenedione, 11-
deoxycortisol, and 21-deoxycortisol. 
The aim of this study was to develop a liquid chromatography-tandem mass 
spectrometry method (LC-MS/MS) for simultaneous and sensitive measurement of six 
adrenal steroids (pregnenolone, progesterone, 17-hydroxyprogesterone, 11-deoxycortisol, 
cortisol, and androstenedione) in serum. This panel covers four subtypes of enzyme 
deficiency in CAH (Figure 5.1). 
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Figure 5.1: Steroidogenesis pathway 
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5.2 Methods and materials  
5.2.1 Chemicals, reagents and solutions 
Methanol and acetonitrile (Burdick and Jackson High Purity Solvent) were from 
VWR (West Chester, PA, USA). Type 1 water was from a Millipore Synergy System 
(Billerica, MA, USA). Androstenedione (1.0 mg/mL/ampule in acetonitrile; purity 
98.7%), androstene-3,17-dione-2,3,4-13C3 (100 μg/mL/ampule in acetonitrile; purity 
99.9%), progesterone-d9 (100 μg/mL/ampule in acetonitrile; purity 97.7.0%?),  was 
purchased from Cerilliant Corporation (Round Rock, TX, USA). Progesterone, 
pregnenolone, 17-hydroxyprogesterone, 11-deoxycortisol, and cortisol, all purity 99.0%, 
purchased from Sigma-Aldrich (St. Louis, MO, USA). Pregnenolone-17α, 21, 21, 21-d4, 
purity 98.0 atom % D, and cortisol-9, 11, 12, 12-d4,  purity 97.5 atom % D was 
purchased from C/D/N Isotopes (Pointe-Claire, Quebec, Canada). 17-
hydroxyprogesterone-d8 (purity 98.0%) and 11-deoxy cortisol-d7 (purity 98.0%) was 
purchased from Toronto Research Chemicals (North York, Ontario, Canada). 
Hydroxylamine hydrochloride was purchased from Sigma-Aldrich. Charcoal dextran 
stripped human serum was purchased from Equitech-Bio Inc. (Kerrville, TX, USA). A 
reverse phase column, Kinetex C18 analytical column (2.1 x 50 mm, 2.6 μm) was 
purchased from Phenomenex (Torrance, CA, USA). 
5.2.2 Calibrators and Quality Controls 
Calibrators were prepared by spiking charcoal dextran stripped human serum with 
100-fold standard mixture solution then serially diluted with stripped human serum. 
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Quality controls were prepared by spiking pooled patient serum with a separately 
prepared standard mixture solution. The concentrations of calibrators and quality controls 
are listed in Table 5.1. All solutions were stored at -20°C in Pyrex 16 X 100 mm 
(Corning, NY, USA) culture tubes until use.   
5.2.3 Sample Preparation 
Serum (500 μL) collected using standard venipuncture in red top vacutainer tubes 
(BD, Franklin Lakes, New Jersey, USA) was vortex mixed with the IS solution (100 µL; 
working internal in 1:1 methanol:water v/v, Table 5.2), followed by addition of 2 mL of 
methyl-tert butyl ether.  Vortex mixed for 1 min and centrifuged at 2,000 g for 10 min. 
The organic layer was transferred into a glass tube and dried under a flow of nitrogen at 
35°C for 10 min. Hydroxylamine (50 µL; 1.5 M) was added to the residue and vortexed 
for 5 s then incubated at room temperature for 15 min. Methyl-tert butyl ether (1 mL) 
was added, vortexed, and centrifuged at 2,000 g for 2 min. The organic layer was 
transferred into a glass tube and dried under a flow of nitrogen at 35°C for 10 min. The 
residue was then reconstituted with 1:1 methanol:water (v/v) (100 µL) and injected (50 
μL) in the LC-MS/MS system for analysis.  
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Table 5.1: Steroid Concentrations in Calibrators and Quality Controls (ng/mL) 
ANALYTE 
Calibrator Spiked QC 
Cal 1 Cal 2 Cal 3 Cal 4 Cal 5 Cal 6 Low Mid High 
Androstenedione 0.025 0.05 0.1 0.4 1.6 6.4 0 2.56 5.12 
Pregnenolone 0.125 0.25 0.5 2 8 32 0 12.8 25.6 
Progesterone 0.125 0.25 0.5 2 8 32 0 12.8 25.6 
17-
hydroxyprogesterone 
0.1 0.2 0.4 1.6 6.4 25.6 0 10.2 20.5 
11-deoxycortisol 0.05 0.1 0.2 0.8 3.2 12.8 0 5.12 10.2 
Cortisol 2 4 8 32 128 512 0 205 410 
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Table 5.2: Isotope-Replaced Working Internal Standard 
Internal standard Conc. (ng/mL) 
Androstendione-13C3 1.6 
Pregnenlone-d4 8 
Progesterone-d9 8 
17-hydroxyprogesterone-d8 1.6 
11-deoxycortisol-d7 3.2 
Cortisol-d4 80 
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5.2.4 LC-MS/MS method 
This method was developed on a Thermo Fisher Transend LC system coupled to a 
TSQ Vantage mass spectrometer. The duplex LC system consisted of robotic sampling 
arms and a refrigerated sampling compartment for six 96-well plates followed by 
independent inline degassers and LC pumps.  The mobile phase consisted of water (A) 
and methanol (B). Samples were injected onto a Kinetex C18 analytical column at a flow 
rate of 0.6 mL/min as per Table 5.3. The total run time between injections for one 
channel is 7.4 min. Mass spectrometer was operated in positive ionization mode with 
spray voltage of 3500 V, vaporizer temperature of 550 °C, and capillary temperature of 
248 °C. The sheath gas was set at 40 U, aux gas at 30 U. SRM scan type was used with 
scan width of m/z ±1.0 and scan time of 0.01 s. Both the peak width of Q1 and Q3 was 
used with 0.7. MS/MS transitions used for monitoring steroids and their internal 
standards are listed in Table 5.4. Calibration was based on peak area ratios of analyte to 
the IS over the analyte concentrations with 1/x
2
 fitting.  
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Table 5.3: CAH Steroid Panel LC Conditions for Turbo and Analytical Columns 
Time (s) 
Analytical column eluting 
Flow rate (mL/min) 
A:B* 
(%) 
20 0.6 90:10 
90 0.6 70:30 
45 0.6 50:50 
45 0.6 30:70 
90 0.6 0:100 
150 0.6 90:10 
*Mobile phase: A, water; B, methanol. 
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Table 5.4: CAH Steroid Panel SRM Transitions  
Compounds Ion transition (m/z) 
CE 
(eV) 
Androstenedione 317.2>112.1* 26 
 
317.2>124.1 29 
Androstenedione -13C3 320.3>115.1 28 
Pregnenolone 332.2>86.1* 26 
 
332.2>300.3 20 
Pregnenolone -d4 336.3>90.1 26 
Progesterone 345.3>112.1 33 
 
345.3>124.1* 34 
Progesterone-d9 354.4>128.1 30 
17-hydroxyprogesterone 361.2>112.1* 29 
 
361.2>124.1 32 
17-hydroxyprogesterone -d8 369.3>115.1 31 
11-deoxycortisol 377.2>112.1 30 
 
377.2>124.1* 31 
11-deoxycortisol-d7 384.3>128.2 35 
Cortisol 393.2>91.1 52 
 
393.2>136.1* 25 
Cortisol-d4 397.2>136.1 27 
* Transition used for quantification. 
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5.2.5 Method validation 
Initial ion suppression evaluation was performed by post-column infusion of a 
saline solution containing 6.25 µg/mL of the internal standards, while extracted patient 
samples (3 males and 3 females) without IS were injected into the system. Relative ion 
suppression was studied to test whether the IS accounted for ion suppression for the 
analytes in the matrix. It is evaluated by extracting and injecting a charcoal stripped 
serum spiked with 1.0 to 160 ng/mL of the steroids, 6 patient samples (3 males and 3 
females), and 1:1 mixtures of patient samples with the spiked charcoal stripped serum. 
The criteria for passing is the response ratio (analyte/IS) of each 1:1 mixture was within 
20% of the theoretical response calculated from averaging the measured values for the 
patient and spiked charcoal stripped serum. Analytical measurement range (AMR) was 
examined in triplicate by serially diluting spiked pooled serum with charcoal stripped 
serum. From these samples, the AMR was determined based on three factors: accuracy 
within 100 ± 20%, a coefficient of variation (CV) within 20%, and a signal to noise 
greater than 10. Carryover was performed in triplicate and consisted of running a high 
spiked sample and a low unspiked sample with a concentration below a typical late-night 
specimen in the sequence of low1-high-low2, where low2 is a re-injection of low1. 
Carryover is considered acceptable if low2 is within 20% of low1 and low2 is within 3 
standard deviations of the low1 value. The standard deviation was determined using only 
low1 values. Precision was evaluated using a modified protocol based on the Clinical 
Laboratory and Standards Institute (CLSI) EP10-A3 guideline (Wayne, PA, USA) and 
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included running the sequence mid-hi-low-mid-mid-low-low-hi-hi-mid once a day for 5 
days using patient derived samples to determine both within run and total CVs. 
5.3 Results and Discussion 
A representative chromatogram is seen in Figure 5.2. No significant ion 
suppression was observed. The mean difference for the mixing study samples (n=6) for 
each steroid is seen in Table 5.5. AMR ranged from 0.02 to 1456.51 ng/mL (Table 5.5) 
with the accuracies between from 90.6 to 134.6%. No significant carryover was observed 
up to the concentrations in Table 5.5 for all except progesterone and pregnenolone which 
had increased carryover. The total precisions ranges from 4.3 to 37.1% for all compound 
concentrations of 0.3 to 512.1 ng/mL (Table 5.6).  
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Figure 5.2: Representative Chromatograms of Extracted Patient Serum. Samples contain 
0.43 ng/mL androstenedione, 0.30 ng/mL pregnenolone, 0.45 ng/mL progesterone, 0.51 
ng/mL 17-hydroxyprogesterone, 0.97 ng/mL 11-deoxycortisol, and 103 ng/mL cortisol. 
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Table 5.5: CAH Steroid Panel Validation Data Summary 
Compounds 
Mixing 
Study 
Average 
difference 
(%) 
AMR 
lower limit 
of 
quantitation 
(ng/mL) 
AMR 
upper limit 
of 
quantitation 
(ng/mL) 
Carryover 
concentrations 
(ng/mL) 
Androstenedione 7.4 0.02 31.42 14.9 
Pregnenolone 10.6 0.16 122.15 76.8 
Progesterone -3.7 0.3 165.63 74.9 
17-hydroxyprogesterone -14.2 0.22 27.27 55.0 
11-deoxycortisol 12.6 0.1 15.43 35.5 
Cortisol -2.5 1.6 1456.51 1131.7 
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Table 5.6: CAH Steroid Panel Precision 
Compounds 
 
Androstenedione Pregnenolone Progesterone 
17-
hydroxyprogesterone 
11-
deoxycortisol 
Cortisol 
N 
Low 15 12 14 15 15 15 
Mid 15 15 15 15 15 15 
High 15 14 15 15 15 15 
Grand Mean (ng/mL) 
Low 0.4 0.3 0.3 0.5 1.0 102.9 
Mid 4.2 9.8 14.3 9.9 8.3 313.2 
High 7.6 19.9 28.1 18.7 15.2 512.1 
Total %CV 
Low 8.2% 37.3% 21.7% 16.7% 15.0% 6.0% 
Mid 10.7% 30.1% 10.8% 11.5% 13.3% 4.3% 
High 7.9% 33.4% 9.7% 9.7% 13.9% 4.6% 
Total SD (ng/mL) 
Low 0.0 0.1 0.1 0.1 0.1 6.2 
Mid 0.5 3.0 1.5 1.1 1.1 13.4 
High 0.6 6.6 2.7 1.8 2.1 23.5 
Within Run SD (ng/mL) 
Low 0.0 0.1 0.1 0.0 0.2 3.0 
Mid 0.2 0.5 0.7 0.5 0.6 7.1 
High 0.4 2.5 4.0 1.5 2.6 17.1 
Within Run %CV 
Low 3.3% 17.4% 15.6% 3.6% 15.6% 2.7% 
Mid 3.9% 6.9% 4.0% 5.0% 7.3% 2.3% 
High 4.5% 18.1% 13.4% 7.4% 15.5% 3.4% 
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5.4 Conclusion 
To my knowledge, no assay clinically available performs this combination of 
steroids. This assay allows for the detection and determination of all five variants of CAH 
in one run and would be useful for secondary diagnosis or treatment monitoring of 
patients known to have CAH. As such, this clinical assay would be a welcomed addition 
to the field.  
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CHAPTER VI                                                                             
OVERALL CONCLUSIONS AND FUTURE DIRECTIONS 
 
6.1 Chapter 2 
The method validation protocol presented in this chapter has been completely 
developed in-house and is required for all clinical LC-MS/MS assays. A complete 
version of this protocol along with statistical method of assessment is available at CC and 
is stored in LabQMS. LabQMS is the Pathology and Laboratory Medicine Institute’s 
laboratory control system. This protocol provides detailed step-by-step procedures for 
method validation from data acquisition to data analysis which is more complete 
compared to existing guidelines but flexible enough to be used for vastly different 
analytes. We use this protocol for all newly developed LC-MS/MS methods at the CC 
many of which have been published [1-6]. This protocol continues to be useful and will 
morph as the technology evolves and regulations change.  We are currently updating this 
protocol to extend to other test types and to improve the validation of assays. 
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6.2 Chapter 3 
6.2.1 Prospective follow-up study 
 In order to properly test the potential biomarker (cortisone) established with this 
study, a prospective follow-up study needs to be performed with a similar high risk 
population then a normal risk group. These studies need to be long term (5-10 yr), will 
require inter-hospital cooperation, and a significant funding source. 
6.2.2 NHANES proposal 
 A NHANES proposal to get access to the large cohort samples would be possible after 
significant vetting using a smaller cohort study. 
6.3 Chapter 4 
The salivary cortisol assay is in the process of being put into clinical use but it has 
also been used for a few clinical studies. An example is a study to determine if there is a 
longer term cycle being imposed on cortisol outside of the diurnal variation. Further 
studies are also being performed to determine the changes associated with cortisol 
injection into joints and to study a new mobile app assay. 
6.4 Chapter 5 
Few methods have comprehensive coverage of all types of CAH and many are for 
research only. We expect to offer this assay for clinical production in our laboratory. To 
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institute the assay, we still need medical technologist training, assay estimated cost, and a 
complete protocol for clinical use. 
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